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Abstract 
I 
Eukaryotic gene transcription is tightly regulated, such that a specific transcriptional program 
is turned on only when required in an organ/tissue/cell specific manner. The set of genes that 
is turned on in response to an environmental cue is determined by the activation of a selective 
group of transcription factors. Once activated, transcription factors bind specifically to DNA 
response elements in the regulatory region of the target genes and thereby activate 
transcription. This activation is mediated by the recruitment of other proteins to the promoter, 
the so-called co-activators. These proteins are recruited as part of multi-protein complexes via 
a direct or indirect interaction with chromatin bound transcription factors, resulting in the 
activation of transcription. 
 
An emerging class of proteins involved in the regulation of transcription are bridging factors. 
These proteins do not harbour any known co-activator function or domain, but are recruited to 
the promoter via a direct interaction with transcription factors, and mediate an increase in 
transcriptional activity, presumably through the recruitment of other co-activators. Therefore 
they can be considered as co-activators. Proteins belonging to the class of LIM-domain 
proteins can function as co-activators via this mechanism. Our group could show that the 
nuclear isoform of the LIM-domain protein Trip6, nTrip6, is an important regulator of the 
transcription factors AP-1 and NF-κB. nTrip6 functions as a novel transcriptional co-activator 
for both transcription factors. Moreover, nTrip6 is essential for the repression of AP-1 and 
NF-κB by another transcription factor, the glucocorticoid receptor (GR). GR represses the 
transcription of AP-1 and NF-κB target genes without binding to DNA, but by being tethered 
to the promoter bound by AP-1 or NF-κB. nTrip6 is essential for this so-called trans-
repression, by mediating the tethering of GR to the promoter. This negative crosstalk is 
reciprocal: AP-1 and NF-κB can trans-repress GR by a tethering mechanism. 
 
In this work I showed that nTrip6 act as a selective co-activator for a subset of AP-1 dimers. 
Moreover, the interaction of AP-1 dimers with nTrip6 determines the ability of GR to trans-
repress these AP-1 dimers, since GR is tethered to the promoter via its interaction with 
nTrip6. Similarly, nTrip6 acts as a co-activator for GR, and mediates the tethering of AP-1 
and NF-κB to promoter-bound GR, as a first step in the trans-repression of GR by AP-1 and 
NF-κB. The co-activator function of nTrip6 necessitates its dimerisation through two 
dimerisation domains in its N-terminus. This dimerisation enables the recruitment of other 
proteins, presumably co-activators, to the promoter. These properties of nTrip6 are most 
likely common to other LIM-domain proteins. The ability of transcription factors to interact 
with several LIM-domain proteins enables fine tuning of the transcriptional response, by the 
recruitment of different co-activator complexes, and by the possibility of repressing crosstalks 
with other transcription factors. 
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Abstract 
III 
Die transkriptionelle Koaktivatorfunktion  
des LIM-Domänenproteins  
nTrip6 
 
Die Transkription eukaryotischer Gene ist streng reguliert. Ein spezifisches transkriptionelles 
Programm wird in einem Organ/Gewebe/Zell-spezifischen Kontext nur ausgeführt wenn es benötigt 
wird. Die Gene, welche als Antwort auf einen Umweltreiz angeschaltet werden, werden durch die 
Aktivierung einer selektiven Gruppe von Transkriptionsfaktoren aktiviert. Nach ihrer Aktivierung 
binden Transkriptionsfaktoren an spezielle DNA-Erkennungssequenzen in der regulativen Region 
ihrer Zielgene und leiten die Transkription dieser ein. Diese Aktivierung wird durch die Rekrutierung 
von anderen Proteinen, den so genannten Ko-Aktivatoren, an den Promotor vermittelt. Diese Proteine 
werden als Teil von Multi-Protein Komplexen mittels einer direkten oder indirekten Interaktion mit 
dem chromatin-gebundenen Transkriptionsfaktor rekrutiert, welches zur Aktivierung der Transkription 
führt.  
Eine neu entstandene Klasse von Proteinen, welche in der Regulation der Transkription eine Rolle 
spielen, sind Brückenfaktoren. Diese Proteine enthalten keine bekannten Ko-Aktivator Funktionen 
oder Domänen, werden allerdings mittels einer direkten Interaktion mit den Transkriptionsfaktoren an 
den Promotor rekrutiert, und führen dabei zu einer Steigerung in der transkriptionellen Aktivität, 
vermutlich durch die Rekrutierung zusätzlicher Ko-Aktivatoren. Proteine, welche zur Klasse der LIM-
Domänen Proteine gehören, können mittels dieses Mechanismus als Ko-Aktivatoren fungieren. Unsere 
Gruppe konnte zeigen, dass die nukleäre Isoform des LIM-Domänen Proteins Trip6, nTrip6, ein 
wichtiger Regulator der Transkriptionsfaktoren AP-1 und NF-κB ist. nTrip6 ist ein neuer 
transkriptioneller Ko-Aktivator für diese beiden Transkriptionsfaktoren. Des weiteren ist nTrip6 
essentiell für die Repression von AP-1 und NF-κB durch einen weiteren Transkriptionsfaktor, den 
Glukokortikoidrezeptor (GR). Der GR reprimiert die Transkription von AP-1 und NF-κB Zielgene 
ohne direkte Bindung an DNA, sondern mittels direkter Anbindung an die Promotor-gebundenen 
Transkriptionsfaktoren. nTrip6 ist essentiell für diese so genannte „Trans-Repression“, in dem es die 
Anbindung des GR an den Promotor vermittelt. Dieser negative „Crosstalk“ ist reziprok: AP-1 und 
NF-κB können ebenfalls den GR mittels Anbindung trans-reprimieren. 
In dieser Arbeit konnte ich zeigen, dass nTrip6 ein selektiver Ko-Aktivator für AP-1 ist. Des weiteren 
bestimmt die Interaktion der AP-1 Dimere mit nTrip6 die Fähigkeit des GR zur Trans-Repression, da 
der GR mittels Interaktion mit nTrip6 an den Promotor herangeführt wird. Ferner fungiert nTrip6 als 
Ko-Aktivator für den GR, und vermittelt die Rekrutierung von AP-1 und NF-κB an den Promotor-
gebundenen GR, wobei es sich um den ersten Schritt in der „Trans-Repression“ von GR durch AP-1 
und NF-κB handelt. Um als Ko-Aktivator fungieren zu können, muss nTrip6 mittels zweier Domänen 
in seinem N-Terminus dimerisieren. Diese Dimerisierung ermöglicht die Rekrutierung weiterer 
Proteine, vermutlich Ko-Aktivatoren, an den Promotor. Diese Eigenschaften von nTrip6 sind 
vermutlich auch bei anderen LIM-Domänen Proteine zu finden. Die Fähigkeit von 
Transkriptionsfaktoren mit verschiedenen LIM-Proteinen zu interagieren ermöglicht eine 
Feinabstimmung der transkriptionellen Regulation durch Rekrutierung verschiedener Ko-Aktivator-
Komplexe oder durch den Crosstalk mit anderen Transkriptionsfaktoren.  
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1. Introduction 
 
Eukaryotic gene transcription is tightly regulated, such that a specific transcriptional program 
is turned on only when required in an organ/tissue/cell specific manner. The set of genes that 
is turned on in response to an environmental cue is determined by the activation of a selective 
group of transcription factors. Depending on the transcription factor, several mechanisms can 
be used for their activation, ranging from transcriptional induction, to posttranslational 
modifications or translocation of the cytosolic transcription factor to the nucleus. Once 
activated, transcription factors bind, via a DNA binding domain (DBD), specifically to DNA 
response elements in the regulatory region of the target genes and thereby activate 
transcription via a trans-activation domain.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This activation is mediated by the recruitment of other proteins to the promoter, the so-called 
co-activators. These proteins are recruited as part of multi-protein complexes via a direct or 
indirect interaction with chromatin bound transcription factors, resulting in the activation of 
transcription. Co-activators can be grouped into different classes depending on their functions 
and properties (Marmorstein and Trievel, 2008; McKenna and O'Malley, 2002; Naar et al., 
2001; O'Malley et al., 2008; Peterson and Laniel, 2004; Smith and Denu, 2008).  
1) Histone tail modifiers: 
Post-translational modifications of histones, like acetylation, methylation, 
phosphorylation, ubiquitination or/and sumoylation is an essential co-activation 
mechanism. The best-characterized modification is acetylation, catalyzed by histone 
acetyltransferases (HATs) like CREB binding protein (CBP) or p300. CBP/p300 
provides a bridge directly interacting both with a wide variety of transcription factors, 
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such as C/EBPb, Ets, AP-1, NF-AT and GATA family members, and with components 
of the basal transcriptional machinery, including TBP, TFIIB, TFIIE and TFIIF. (Liu 
et al., 2004). Another class of proteins with an intrinsic HAT function are members of 
the p160/SRC/NCoA co-activator family: NCoA-1 (Nuclear receptor co-activator 1), 
also called SRC-1, NCoA-2 also called SRC-2, TIF2 or GRIP1 and NCoA-3, also 
called p/CIP, RAC3, ACTR, AIB1 or TRAM-1. These proteins were first identified as 
co-activators for nuclear receptors, but they are also capable of influencing the 
transcriptional regulation of other transcription factors, like STAT and NF-κB. The 
function of NCoA proteins is the recruitment of other co-activators, which harbour 
histone acetyl-transferase activity (HAT), like p300, CBP and p/CAF and co-factors 
with histone methyl-transferase activity (HMT), like CARM1 and PRMT1. In 
addition, NCoA-1 and NCoA-3 posses a weak intrinsic HAT activity at the C-terminus 
(Lodrini et al., 2008).  
Histone methylation can be grouped into two families, lysine methylation and arginine 
methylation, which are catalyzed by lysine methyltransferases (HKMTs) and protein 
arginine methyltransferases (PRMTs), respectively. Nearly all HKMTs have the 
evolutionally conserved SET (SU(VAR)3-9, enhancer-of-Zeste, Trihorax) domain that 
is responsible for lysine methylation activity. Members of the protein arginine methyl 
transferase (PRMT) catalyzes the generation of di-methyl arginine residues on 
substrate proteins using S-adenosyl methionine (SAM) as the methyl donor. As an 
example, CARM1 methylates histone H3 and p300/CBP, thereby altering chromatin 
architecture and impacting transcriptional initiation. (Kleinschmidt et al., 2008; 
Purandare et al., 2008). The histone tail modifiers change the global charge of the 
histones resulting in a change of chromatin structure. Furthermore, these modifications 
also serve as docking sites for other proteins, e.g. other co-activators like chromatin 
remodellers. 
 
2) Chromatin-remodellers: 
The human SWI/SNF complex is a large multi-subunit complex of approximately 
2MDa in size. The exact subunit composition of the SWI/SNF complex varies, 
although it contains at least nine or more subunits in humans. In humans there are two 
major subfamilies of the SWI/SNF complex: BAF (BRG1 or BRM-associated factor) 
and PBAF (polybromo-associated factor). These two groups are similar in their 
composition, sharing eight subunits (BRM or BRG1, BAF170, BAF155, BAF60a, 
BAF57, BAF53, actin, and BAF47). However, BAF contains BAF250, while PBAF 
contains BAF180 (also known as polybromo) and BAF200. All SWI/SNF complexes 
contain an ATPase subunit, which is either BRM (brahma) or BRG1 (brahma-related 
gene 1). These ATPase subunits are mutually exclusive. The ATPase subunit of 
SWI/SNF contains a bromodomain. A bromodomain is a protein domain that 
recognizes acetylated lysine residues such as those on the N-terminal tails of histones. 
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This recognition is often a prerequisite for protein-histone association and chromatin 
remodelling (Halliday et al., 2008). Via chromodomains these complexes are able to 
identify methylated histone tail. After binding to their specific docking site chromatin 
remodellers act by sliding the nucleosomes positioning relative to the DNA. Through 
this sliding the complex enables other proteins, e.g. co-activators, to be recruited to the 
promoter and to initiate transcription. 
 
3) Mediator complex: 
The human Mediator complex is a multi-subunit co-activator that regulates RNA 
polymerase II-dependent transcription (Conaway et al., 2005a; Conaway et al., 2005b). 
The mediator complex plays multiple roles in regulating the pre-initiation complex 
(PIC), which minimally consists of TFIIA, IIB, IID, IIE, IIF, IIH, and RNA 
polymerase II (Pol II). The Mediator complex interacts directly with Pol II and is 
involved in the recruitment of this complex to gene promoters. It also stimulates the 
TFIIH-dependent phosphorylation of the Pol II C-terminal domain, which is critical 
for transcription initiation. Furthermore, the mediator complex is a general target of 
DNA-binding transcription factors. Thus, the mediator complex is believed to function 
in part by communicating regulatory signals from promoter and enhancer-bound 
transcription factors directly to the PIC. Furthermore, this co-factor is able to interact 
and recruit other co-activators required for initiating transcription, like proteins 
harbouring a HAT-domain. One simple way in which Mediator activity is controlled is 
through subunit exchange: addition or subtraction of subunits to alter its biochemical 
function. For instance, a cdk8 sub-complex (consisting of cdk8, cyclin C, Med12 and 
Med13) can reversibly associate with the ‘core’ Mediator to inhibit its co-activator 
function. (Meyer et al., 2008).  
 
Another class of proteins involved in the regulation and activation of transcription are 
bridging factors. These proteins do not harbour any known co-activator function like HAT or 
HMT, but are recruited to the promoter via a direct interaction with transcription factors, and 
mediate an increase in transcriptional activity, presumably through the recruitment of other 
co-activators. Therefore they can be considered as co-activators. Proteins belonging to the 
class of LIM-domain proteins can function as co-activators via this mechanism. 
 
1.1. The family of LIM-domain proteins 
 
The LIM-domain was first identified and described in three homeo-domain proteins, Lin1-l, 
Isl-1 and Mec-3. LIM-domains are cystein-and histidin rich regions. Each LIM-domain 
consists of 2 zinc-fingers, which harbour Zn2+-ions, resulting in the specific structure of the 
zinc-finger (Dawid et al., 1998).  
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Based on sequence homology studies LIM-domain proteins were separated into three 
different classes:  
Class I LIM-domain proteins contains LHX (LIM homeodomain)-proteins, LMO´s (LIM only 
proteins) and LIM-kinases (LIMK). Their LIM domains appear in tandem repeats and these 
proteins are localised mainly within the nucleus. Their function is diverse; LHX-proteins 
function as transcription factors by interacting with DNA directly through their homeo-
domain, whereas LMO-proteins act as transcriptional co-activators. LIM-kinases are found in 
the cytosol as well as in the nucleus, where they are involved in actin polymerisation and are 
part of the Ras signalling pathway. 
Class II LIM-domain containing proteins show a high sequence similarity. They are mainly 
composed of LIM-domains. Members of this class are CRIP and CRP. They are localised in 
the cytosol and function as bridging factors to associate proteins into signalling complexes. 
Interactions between CRP and Zyxin, a member of class III, are reported (Schmeichel and 
Beckerle, 1997, 1998).  
Class III forms a very heterogeneous group of proteins mainly localised in the cytosol. 
Typical members of this class are proteins belonging to the Zyxin- and Paxillin-families. 
Members of the Zyxin-family, comprising Ajuba, LIM-D1, LPP and Trip6, are associated to 
focal adhesion sites. They are found in multi-protein complexes which are associated to cell 
matrix attachments or cell-cell contacts. They are involved in signal transduction pathways by 
activating signalling proteins (Turner, 2000), or by functioning as bridging factors for proteins 
involved in signalling (Matsuya et al., 1998). Moreover, members of this family have been 
reported to act as transcriptional co-activators for distinct classes of transcription factors. One 
of the best studied class III LIM domain protein involved in transcription regulation is the 
androgen receptor (AR) co-activator 55 (ARA55)/Hic-5 (Guerrero-Santoro et al., 2004). 
Other family members like Paxillin are involved in trans-activation of androgen receptor as 
well (Kasai et al., 2003). Lipoma preferred binding partner, LPP, functions as a co-activator 
for the ETS domain transcription factor PEA3 (Guo et al., 2006). Another class III LIM-
C C C H 
C C    D/H/C C 
Zn Zn 
17-19 16-20
2 2 2 2
2
a) b)
Fig 2. Structure of the LIM-domains 
a) double zinc-finger motif of a LIM-domain 
b) 3D-reconstruction of a crystallised LIM-domain 
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domain protein, LIM-D1, functions as an AP-1 co-activator (Feng et al., 2007). Finally, 
nTrip6 the nuclear isoform of Trip6, acts as a co-activator for AP-1 and NF-κB (Kassel et al, 
2004). 
 
1.1.1. The LIM-domain protein Trip6 
 
Trip6 was first described and characterised in 1995 as thyroid hormone receptor interacting 
protein 6 (Trip6) (Lee et al., 1995), and its function and role was not identified at that time. 
The protein Trip6 comprises 476 amino acids encoded within 9 exons (Fig. 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Trip6 is mainly localised in the cytosol, where it co-localises with the actin filament (Cuppen 
et al., 2000) and is enriched at focal adhesions and at cell-cell contact sites, where it 
influences cell adhesion and migration (Bai et al., 2007; Lai et al., 2005; Lai et al., 2007; Xu 
et al., 2004; Yi et al., 2002). The three C-terminal LIM-domains of Trip6 are protein-protein 
interaction surfaces and not used to bind to DNA. They are highly conserved among the 
family members and all members of the Zyxin family contain three LIM-domains at the C-
terminus (Wang and Gilmore, 2001).  
 
Trip6 localisation in the cytosol was attributed to the presence of a functional nuclear export 
signal (NES) within its N-terminus, encoded by amino acids 100 to 107 (Wang and Gilmore, 
2001). When this part of the protein was deleted, Trip6 accumulated within the nucleus 
(Wang and Gilmore, 2001). The NES, which is conserved among the different family 
members (Wang and Gilmore, 2001), is encoded within exon 3 and it is a leucine rich region 
(100LSSTLAEL107). Leucine-rich areas are known interaction surfaces for Crm-1. This protein 
is responsible for the nuclear export of proteins containing a NES-sequence. When Crm-1 is 
inhibited by Leptomycin B, Trip6 accumulates in the nucleus (Wang and Gilmore, 2001). 
 
 
Trip6 LIM 1
NES 
LIM 2 LIM 3 
AUG 
Fig.3: Structure of Trip6 
a) Trip6 is encoded within 9 
exons; The nuclear export 
signal (NES) is encoded 
within Exon 3, Exons 5-9 
encode the 3 LIM domains 
b) Schematic drawing of the 
Trip6 protein 
Exon 1 Exon 2 Exon 3 Exon 5 Exon 9 Exon 8 Exon 7 Exon 6 Exon 4 
LIM 1 LIM 2 LIM 3 NES 
a) 
 
 
 
 
 
 
b) 
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A possible nuclear function of Trip6 has been attributed to its putative capacity to translocate 
to the nucleus (Wang and Gilmore, 2001). However, this hypothesis has been dismissed, and 
the nuclear function of Trip6 was attributed to a shorter, exclusively nuclear isoform of Trip6, 
nTrip6 (Kassel et al., 2004). 
 
1.1.2. The nuclear isoform of the LIM-domain protein Trip6, nTrip6 
 
Our group identified a nuclear isoform of Trip6, nTrip6. This protein is shorter in size, lacks 
the NES, and is therefore exclusively present in the nucleus, and contains all three LIM-
domains (Kassel et al., 2004) (Fig. 5).  
 
 
 
 
 
 
 
 
nTrip6 is generated via alternative translation initiation at an alternative AUG start codon, 
located in exon 3, directly within the NES (Winter, 2007). Translation from this secondary 
AUG results in a truncated and non-functional NES, and nTrip6 is thus localized in the 
nucleus. 
 
1.1.3. nTrip6 functions as a co-activator for NF-kB RelA/p65 and for AP-1 c-Jun:c-Fos 
 
Our group could show that nTrip6 functions as a novel transcriptional co-activator for the 
transcription factors AP-1 and NF-κB (Kassel et al., 2004). Recruited to AP-1 or NF-κB 
nTrip6 LIM 1 LIM 2 LIM 3
AUG 
Trip6  LIM 1
NES 
LIM 2 LIM 3 
AUG 
50kDa 
 
 
 
 
40kDa 
 
 
 
 
Fig.4: The NES is highly conserved among the Zyxin family members 
from Wang et al., 2000 
Fig.5: Schematic comparison 
of the different Trip6 
isoforms 
 
Nuclear Export Signals  
of  
Zyxin Family Members 
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bound to target promoters, nTrip6 acts as or binds additional co-activator(s). The interaction 
between the transcription factors and nTrip6 is mediated via its LIM-domains. Through a 
direct protein-protein interaction with LIM-domain 1 p65 as well as Fos are interacting with 
nTrip6 resulting in its recruitment to the promoter. Reducing the level of nTrip6 by siRNA 
decreased and over-expression increased the trans-activation by both AP-1 and NF-κB, 
suggesting that endogenous levels of nTrip6 can be limiting for AP-1 and NF-κB activity. 
 
 
 
 
 
 
 
 
 
nTrip6 is not only functioning as a co-activator for AP-1 and NF-κB, it is also mediating the 
repression of both transcription factor families by the glucocorticoid receptor (GR) to the 
(Kassel et al., 2004). We do not yet know the detailed mechanism of transcriptional regulation 
by nTrip6. Apart from the three LIM domains in the C-terminal half, nTrip6 carries no other 
known functional domain, motif, or catalytic activity that could mediate its co-activator 
function. We favour, therefore, the hypothesis that nTrip6 recruits additional co-activators by 
protein–protein interaction via its LIM-domains. 
 
1.2.The transcription factor family AP-1 
 
The Activator Protein-1 (AP-1) family of transcription factors was one of the first identified 
mammalian transcription factors. AP-1 consists of homo-and hetero-dimers, composed of the 
Jun (c-Jun, JunB, JunD), Fos (c-Fos, FosB, Fra1, Fra2) and CREB/ATF2 (ATF2, ATF3) 
subfamilies (Angel and Karin, 1991). AP-1 dimers bind to the consensus TPA responsive 
element (TRE) or to the related CREB responsive element (CRE). The AP-1 transcription 
factors belong to the class of basic zipper (bZip) sequence specific DNA-binding proteins. 
Via their leucine zipper motif the homo- or heterodimers are formed and bind DNA by their 
basic motif. The formation of each dimer depends on their relative dimerisation affinities, and 
on the abundance of each of the Jun, Fos and ATF proteins available in the cell at a given 
time. Fos members of the family cannot form stable homodimers but heterodimerise with Jun 
members, e.g. c-Jun:c-Fos. ATF family members can dimerise with c-Jun as well as with 
ATF/CREB family members (Benbrook and Jones, 1994), (Chatton et al., 1994), (Hai and 
Curran, 1991). 
 
 
AP-1 
NF-κB
 
Fig.6: nTrip6 functions as a co-activator for AP-1 
and NF-κB 
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The different AP-1 hetero-dimers have different affinities to responsive elements. Jun hetero-
dimerising with Fos recognises a heptameric responsive element, the phorbol ester 12-O-
tetradecanoate-13-acetate (TPA) response element, TRE (TGAGTCA), which is for example 
present in the promoter of the collagenase I (MMPI) gene, whereas this heterodimer only 
weakly binds to the octameric cyclic-AMP response element, CRE (TTACCTCA), present in 
the c-jun promoter. In contrast, the other prototypical AP-1 heterodimer, c-Jun:ATF2, has a 
weak affinity towards the responsive elements recognised by c-Jun:c-Fos, but has a very high 
affinity to the octameric CRE (Benbrook and Jones, 1990; Hai and Curran, 1991). These 
binding sites have been identified in the regulatory regions of a wide range of genes, 
including transcription factors such as c-Jun and ATF3, matrix-degrading enzymes like 
collagenase I and urokinase plasminogen activator (uPA), cytokines like IFN-γ or adhesion 
molecules such as E-selectin (Angel et al., 1988a; Angel et al., 1988b; Angel et al., 1987; 
Brostjan et al., 1997; Cippitelli et al., 1995; De Cesare et al., 1995; Liang et al., 1996). 
The ability of the AP-1 transcription factor to control many different biological processes 
stems primarily from its structural and regulatory complexity. For example, studies on 
combinatorial variants of AP-1 complexes, using Jun mutants that preferentially 
heterodimerise with either c-Fos or ATF2, revealed opposing roles of c-Jun:c-Fos and c-
Jun:ATF2 dimers in transformation (van Dam et al., 1998). Jun-dependent cell transformation 
can be resolved into at least two distinct and independent processes: anchorage independence 
triggered by c-Jun:c-Fos and growth factor independence triggered by c-Jun:ATF2. These 
differences in the roles of c-Jun:c-Fos and c-Jun:ATF make these dimers particularly 
interesting to study. 
 
1.2.1. The regulation of c-Jun:c-Fos vs. c-Jun:ATF2 
 
The expression of AP-1 target genes is primarily regulated by the relative expression of the 
different dimerisation partners at a given time point. Additionally, the activation status of the 
different dimers determines the program of target genes expressed. Each AP-1 subunit is 
downstream of one or several signalling pathways. For instance, c-Jun:c-Fos dimers are 
mainly activated by the Ras-Raf-MEK-Erk MAP-kinase pathway, whereas c-Jun as well as 
ATF2 are activated by the stress activated MAP-kinases JNK and p38 (Karin, 1996; 
Whitmarsh and Davis, 1996). 
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Thus, different AP-1 dimers are activated by different signalling pathways, and activate 
different target genes. However, little is known about their specific regulation when bound to 
their target promoters. For example, several AP-1 co-activators are known (Bannister et al., 
1995; Halliday et al., 2008; Naar et al., 2001), but whether there are co-activators specific for 
certain AP-1 dimers is not known. Our group showed that nTrip6 acts as an AP-1 co-activator 
(see above). Given that nTrip6 interacts with c-Fos and is recruited in a c-Fos dependent 
manner to TRE-containing target genes (Kassel et al., 2004), one could raise the question of 
the specificity of nTrip6 co-activator function for different AP-1 dimers. 
Fig.7. Different signalling pathways lead to the activation of different AP-1 dimers 
 
a) The induction of c-fos expression is mediated through the activation of the ERK signalling pathway.
Growth factors do stimulate the activation of Ras. Subsequently, the serine/threonine protein kinase Raf-1 
binds to Ras and becomes activated, leading to phosphorylation and activation of the dualspecificity ERK-
kinase, MEK. MEK activates the MAPKs ERK1 and ERK2, which translocate into the nucleus upon 
activation. In the nucleus, ERKs phosphorylate the transcription factor TCF, which is bound to the serum 
response element (SRE) of the c-fos promoter. Phosphorylation of TCF stimulates its trans-activation function
which leads to rapid activation of c-fos transcription. An alternative way to activate c-fos expression is through 
TPA. TPA activates PKC which, through a crosstalk with ERK, stimulates the phosphorylation of TCF which 
regulates the expression of c-fos. (Adapted from Edmunds and Mahadevan, 2004). 
 
b) Regulation of c-Jun and ATF2 through activation of JNK signalling pathway. Cytokines or stress stimulate 
the activation of MEKK1 resulting in the activation of MKK4/7. Both protein kinases are able to activate JNK 
by dual phosphorylation. Activated JNK can phosphorylate AP-1 family members like c-Jun and ATF-2. The 
phosphorylation of AP-1 stimulates its trans-activation function resulting in activation of the transcription, like
c-jun. UV–induced DNA damage mediates the activation of JNK and subsequent phosphorylation of AP-1.
(Adapted from Edmunds and Mahadevan, 2004). 
 
a)                                                                   b) 
Cytokines 
Stress 
Growth 
factors 
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1.2.2. Repression of AP-1 by the Glucocorticoid receptor 
 
Little is known about the mechanisms negatively regulating the response to specific AP-1 
dimers. A physiologically and therapeutically relevant negative control of the AP-1 response 
is exerted by Glucocorticoids (GCs). However, little is known about the dimer specificity of 
this repression. GCs act through the glucocorticoid receptor (GR), which regulates 
transcription by several mechanisms (Kassel and Herrlich, 2007). GR is a ligand-activated 
transcription factor and induces the expression of numerous target genes (Schoneveld et al., 
2004). Liganded GR also interferes with several signal transduction pathways, including the 
Erk (Kassel et al., 2001), JNK (Caelles et al., 1997) and p38 pathways (Imasato et al., 2002). 
Finally, GR directly represses the activity of several other transcription factors, including AP-
1 (Jonat et al., 1990; Schule et al., 1990; Yang-Yen et al., 1990), at the promoter of their 
target genes. This process is referred to as trans-repression (Kassel and Herrlich, 2007). Both 
AP-1 transcriptional activity at promoters and its trans-repression by GR requires the presence 
of the bridging factor nTrip6 (Kassel et al., 2004). Which of these different mechanisms are 
relevant for GR-mediated repression of the different AP-1 dimers remains unknown.  
 
1.3. Glucocorticoids  
 
The glucocorticoids as well as the mineralo-corticoids and the sex specific hormones 
estrogen, progesterone and testosterone belong to the group of steroid hormones. These 
molecules have a lipid-like structure, and the cholesterol is the common subunit. Cortisol 
(Fig. 8), the natural glucocorticoid in human is synthesised in the adrenal cortex and its 
secretion is regulated by the hypothalamic-hypophysis system. The secretion is circadialy 
regulated, but it can also be released upon stress. 
 
 
 
The major impact of glucocorticoids on the organism is on glucose and protein-synthesis 
(Kasambalides and Lanks, 1983, 1985; Norton and Munck, 1980). In glucose-synthesis, 
corticoids lead to the production of glucose out of amino-acids within the liver (gluco-
neogenesis), but at the same time, they hamper the peripheral sugar degradation, resulting in 
Fig.8: The glucocorticoid cortisol 
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an increase of blood-sugar concentration. The protein biosynthesis is hampered by corticoids. 
They interfere with the protein biosynthesis in muscles, bones and lymphatic organs.  
Because of the interference with the protein-biosynthesis within the lymphatic system, 
Glucocorticoids block antibody production. They therefore have an “immuno-suppressive 
effect”. This is used during organ transplantations to suppress the acceptors immune-system 
to tolerate the new organ and avoid rejection. Furthermore, a slowed immune response of the 
lymphocytes has an anti-inflammatory impact. This should hamper an overreaction by the 
organism towards an infection or inflammation. 
Because glucocorticoids are able to interfere with the immune system, they are widely used as 
anti-inflammatory and immuno-suppressive therapeutics. They are used during acute allergic 
reactions, asthma, rheumatic arthritis and chronical inflammations. But there are side effects 
as well, especially during long term exposure to corticoids: diabetes, osteoporosis, adrenal-
cortical obesity, and many more (Barnes, 1998; Barnes and Karin, 1997; Cato and Wade, 
1996). 
 
1.3.1. The Glucocorticoid receptor (GR) 
 
Steroid hormones have a lipophilic character and are therefore able to diffuse passively 
through the cellular membrane. Within the cytosol, they bind to a specific steroid hormone 
receptor belonging to the superfamily of nuclear receptors. These receptors including the 
glucocorticoid receptor (GR) are ligand dependent transcription factors (Beato, 1989; Evans, 
1988; Green and Chambon, 1988; Green et al., 1988; Webster et al., 1988). All family 
members share a common structure, illustrated for the human glucocorticoid receptor (Fig. 9). 
 
 
 
 
 
 
The N-terminus harbours the activation function 1 (AF1). The central DNA-binding domain 
(DBD) is highly conserved among the steroid receptors. It is composed of two zinc finger 
motifs. Both contain a Zn2+-ion linked to the cysteins necessary for the proper formation of 
the zinc finger (Freedman et al., 1988). Each zinc finger has a specific function: the first is 
responsible for binding to DNA, to the glucocorticoid response element (GRE), whereas the 
second zinc finger mediates the homo-dimer formation of the GR (Umesono and Evans, 
Fig.9: Schematic drawing of the domain structure of steroid receptor explained by the glucocorticoid 
receptor 
 
N = amino-terminus; AF1 = activator function 1; DBD = DNA binding domain; h = hinge region; LBD/AF2 = 
ligand binding domain & activator domain 2; C = carboxy terminus; numbers indicate amino acid positions 
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1989). The hinge region (h) connects the DNA-binding domain with the ligand binding 
domain (LBD). The hinge region is essential for the translocation of the receptor upon ligand 
binding into the nucleus (Picard and Yamamoto, 1987). The ligand binding domain is located 
at the C-terminus of the protein and forms a “binding-pocket” comprised of 12 amphipatical 
α-helices and one β-sheet. Upon ligand binding to the “binding pocket”, the pocket is closed 
by reorientation of α-helices 10, 11 and 12, resulting in a conformational change leading to its 
activation. Due to this conformational change the GR is capable of interacting with co-
activator complexes. At the c-terminal end the second activation domain, AF2, as well as the 
trans-activation domain τ2, are located. 
 
In the absence of hormone, GR resides in the cytoplasm as a multiprotein complex composed 
of chaperone proteins hsp90 and hsp70, immunophilin p59, and phosphoprotein p23 (Pratt 
and Toft, 1997). Glucocorticoids diffuse readily across cell membranes and bind to GR in the 
cytoplasm. Binding of hormone to the GR induces the release of hsp90, resulting in a 
conformational change that unmasks the nuclear localization signal. The receptor then 
translocates to the nucleus, where it can act through several modes of action. The 
glucocorticoid receptor regulates the transcription of genes by three basic modes of action: (1) 
binding to glucocorticoid response elements (GREs) in target genes to activate gene 
transcription, (2) inhibition of target gene transcription through direct DNA binding at 
negative GRE (nGREs), and (3) gene regulation by physical interaction with other 
transcription factors (Necela and Cidlowski, 2004). This crosstalk can be either positive, 
enhancing the transcription, or negative, repressing the transcription, depending on the 
transcription factor. The negative crosstalk is referred to as trans-repression. 
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1.3.2. DNA dependent mechanisms-“trans-activation” 
 
The glucocorticoid receptor functions as a transcription factor and is able to bind directly 
DNA through its zinc-finger motif within the DBD. After activation by ligand-binding, it 
translocates into the nucleus and forms homo-dimers. Upon dimer formation it binds to 
glucocorticoid response elements (GRE) within the 5´ upstream region if its target genes and 
initiates the transcription (Fig. 10. 3)). GREs are composed of a palindromic sequence 
(consensus: AGAACANNNTGTTC; (Beato, 1989)). GR target genes are, for example, the 
tyrosin-aminotransferase, which is involved in gluco-neogenesis, MKP-1 (Kassel et al., 2001; 
Lasa et al., 2002), or osteocalcin (Morrison and Eisman, 1993).  
Ligand
1
2
3 4 5
Fig.10: Different modes of glucocorticoid action 
1) the glucocorticoid receptor is retained in the cytosol by interaction with chaperones and kept in an inactive 
state 
2) upon ligand binding the receptor undergoes a conformational change and is released from the chaperone 
complex and translocated into the nucleus where it can function differentially 
3) GR functions as a transcription factor and binds to its responsive elements of its target genes (e.g. iκB-α) 
4) through binding to nGREs the GR is capable of competing with other TFs for binding to their responsive 
elements resulting in trans-repression 
5) the GR is repressing the transcriptional activity of other TFs upon tethering to their promoter 
1. Introduction 
14 
However, the dimer can also bind to negatively regulating nGREs in close proximity to the 
response elements of other transcription factors (Fig. 10. 4)), resulting in a block of 
transcription (Dostert and Heinzel, 2004). This mechanism of action was proposed to account 
for repression of the proopiomelanocortin (Drouin et al., 1993) and prolactin (Sakai et al., 
1988) genes. 
 
1.3.3. DNA-independent mechanisms-“trans-repression” 
 
The immunosuppressive function of glucocorticoids is achieved by repression of the 
expression of pro-inflammatory genes, encoding for instance cytokines, chemokines or cell 
adhesion proteins. Transcription-factors regulating these genes are for example the 
transcription factors of the AP-1 and NF-κB families. No nGRE could be detected in the 
majority of inflammatory genes whose transcription is repressed by GR and transcriptional 
interference was discovered to mostly result from protein-protein interactions between the GR 
and other transcription factors such as AP-1 (Jonat et al., 1990);(Schule et al., 1990; Yang-
Yen et al., 1990), CREB/ATF (Akerblom et al., 1988; Cippitelli et al., 1995), NF-κB 
(Brostjan et al., 1997; McKay and Cidlowski, 1999; Reichardt et al., 2001). In contrast to the 
trans-activation function of GR, where GR forms homo-dimers, only monomers are required 
for trans-repression (Heck et al., 1994) (Fig. 10. 5)).  
The first step in trans-repression is the tethering of activated GR to the promoter-bound 
transcription factors. Our group could show the involvement of nTrip6 in the trans-repression 
of AP-1 and NF-κB by GR (Kassel et al., 2004). The glucocorticoid receptor interacts with 
nTrip6 via its LIM-domains. Given that nTrip6 is recruited as a co-activator to AP-1 and NF-
κB bound promoters, its ability to interact with GR mediates the tethering of GR to the 
promoter, and is thus essential for trans-repression (Kassel et al., 2004). Thus, nTrip6 has a 
dual function in the regulation of AP-1 and NF-κB. On the one hand it is an essential co-
activator for these transcription factors, on the other hand it mediates their repression by GR 
(Fig. 11). 
 
       a)                                                                 b) 
 
 
 
 
 
 
 
 
 
 
 
AP-1 
NF-κB
 
Fig.11: The dual function of nTrip6:  
a) involvement in the positive transcriptional regulation as a co-activator for AP-1  
b) mediating the repression of AP-1 by tethering the GR to promoter bound AP-1 
AP-1 
NF-κB
X 
GR 
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1.3.4. Reverse crosstalk/ repression of GR by other transcription factors 
 
Trans-repression is very often reciprocal. Transcription factors trans-repressed by GR are 
often able to trans-repress GR as well. Therefore, GR-mediated transcription is repressed by 
other transcription factors at promoters containing only GREs, but no binding site for the 
repressing transcription factors, e.g. AP-1 (Lucibello et al., 1990; Schule et al., 1990). They 
were able to show, that the glucocorticoid receptor and transcription factor AP-1 can 
reciprocally repress one another’s transcriptional activation by a novel mechanism that is 
independent of DNA binding. Overexpression of c-Jun prevents the glucocorticoid-induced 
activation of genes carrying a functional glucocorticoid response element (GRE). Mutant 
analysis revealed that the ligand binding and DNA binding domains of GR and the region 
including the leucine zipper of AP-1 are required for repression. These data indicate that 
members of two distinct classes of transcription factors can oppose one another’s activity 
through a mechanism likely involving protein-protein interactions.  
Another family of transcription factors able to influence the transcriptional activity of GR is 
NF-κB (Ray and Prefontaine, 1994; Scheinman et al., 1995).  
Although the repressing transcription factor does not bind directly DNA at the promoter of the 
GR target gene, it is tethered by protein-protein interaction to the promoter bound 
glucocorticoid receptor (Kassel and Herrlich, 2007). Considering the role of nTrip6 as a 
tethering factor for GR in the trans-repression of AP-1 and NF-κB, it might exert a similar 
function in the trans-repression of GR by AP-1 and NF-κB. 
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1.4. Aims of the project 
 
Several questions remain open as to the regulation of transcription by nTrip6. The first part of 
my thesis will deal with the question if nTrip6 is generally required for the regulation of all 
AP-1 dimers, both in terms of its co-activator function and of its role in the trans-repression 
by GR or is it selective for certain AP-1 dimers?  
At the start of my PhD work, nTrip6 had already been shown to interact selectively with 
certain AP-1 family members in vitro, and to increase the transcriptional activity of selective 
AP-1 dimers. My task in this project, involving several people in the laboratory, was more 
specifically to investigate the promoter occupancy, and represents the first part of this 
manuscript (this part of the work has been published in Diefenbacher et al., 2008).  
The second part of this work concerns the putative function of nTrip6 as a co-activator for the 
glucocorticoid receptor, and whether it is involved in the trans-repression of GR by AP-1 and 
NF-κB. A manuscript is in preparation concerning this part of the work. 
And finally, the third part of my work was to identify the mechanism by which nTrip6 exerts 
its co-activator function for AP-1. 
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2. Material and Methods 
 
2.1. MATERIALS 
 
2.1.1. Chemicals 
 
All the chemicals were of the highest quality and were purchased from: 
Acrylamid/N,N´-Methylenbisacrylamid (30:0,8)   Roth, Karlsruhe 
Adenosintriphosphat (ATP)     Sigma, Deisenhofen 
Agarose        Biozym Diagnostik, Hameln 
Ampicillin        Roche Diagnostics, Mannheim 
Bacto-Trypton       Biozym Diagnostik, Hameln 
Blasticidin        Merck, Darmstadt 
Bromphenol blue      Serva, Heidelberg 
Chloroform        Roth, Karlsruhe 
DMEM (synthetic culturmedium)     Gibco BRL, Eggenstein 
D-Glucose        Biozym Diagnostik, Hameln 
Dithiothreitol (DTT)       Roche Diagnostics, Mannheim 
EDTA        Roth, Karlsruhe 
Ethanol        Roth, Karlsruhe 
Ethidiumbromide      Sigma, Deisenhofen 
Formalin        Merck, Darmstadt 
Fetal calf serum (FCS)      Bio Whittaker, Verviers 
Glycerin       Roth, Karlsruhe 
Glycerol        Sigma, Deisenhofen 
Glycylglycin (GLyGly)      Sigma, Deisenhofen 
Yeast-Extract        Biozym Diagnostik, Hameln 
HEPES        Roth, Karlsruhe 
Kanamycin        Biozym Diagnostik, Hameln 
Luciferin        Biosynth AG, Staad (Schweiz) 
Lysisbuffer (5 x passive lysis buffer)      Promega, Madison 
β-Mercaptoethanol       Serva, Heidelberg 
Sodium acetate       Roth,Karlsruhe 
Sodium dodecylsulfate (SDS)     Roth, Karlsruhe 
Mounting medium, Immu-mount     Shandon, Pittsburgh, USA 
N,N,N´,N´-tetramethylenethylendiamine (TEMED)  BioRad, München 
Nonidet P-40 (NP-40)      Sigma, Taufkirchen 
Nucleotide triphosphate      Sigma, Deisenhofen 
PBS         Gibco BRL, Eggenstein 
Phenylmethylsulfonyl-Fluorid (PMSF)   Sigma, Deisenhofen 
2-Propanol       Roth, Karlsruhe 
Bovine serum albumine (BSA)     Sigma, Deisenhofen 
RNasin        Gibco BRL (Eggenstein) 
TPA          
Tris-HCl        Serva, Heidelberg 
Tris base       Roth, Karlsruhe 
Triton X-100        Sigma, Taufkirchen 
Trizol         Invitrogen, Karlsruhe 
Trypsine       Difco, Detroit 
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All other chemicals, unless otherwise stated, were purchased from Carl Rotch GmbH&Co, 
Karlsruhe, Germany; Merck, Darmstadt, Germany or Sigma, Deisenhofen, Germany. 
 
2.1.2. Hardware and consumables 
 
Bacteria-Petri dishes       Greiner, Nürtingen 
8 well Chamber slides      Nunc, Rochester, USA 
Cell Incubator       Hereus, Stuttgart 
Electrophoresis-Chambers      BioRad, München 
Developer for X-Ray-films      Kodak, New Haven 
Dialysis Cassettes      Thermo Scientific, Germany 
ECL Hyperfilm       Amersham, Freiburg, Germany 
Eppendorf-reaction tubes, 1,5 ml     Eppendorf, Hamburg 
ELISA plate reader       
Gel drier        BioRad, München 
Hyperfilm MP®       Amersham Pharmacia Biotech 
Image Reader FLA-3000      Fujifilm, Nakanuma, Japan 
Immobilon-P (PVDF membrane)     Millipore; Bedford, USA 
Heraeus Centrifuge 400R  
with inserts #3324, #8177, #8179     Heraeus instruments 
Coolling Centrifuge J2-HS with inserts JS-13.1 & JA-1  Beckmann, Stuttgart 
Luminometer        Perkin Elmer, 
Perkin Elmer Cetus 9600 Thermocycler    Perkin Elmer Cetus, Norwalk 
Phosphoimagerplate       Fujifilm, Nakanuma, Japan 
Spectralphotometer (Spekol UV/VIS)    Zeiss, Jena 
Stereomicroscope      Zeiss, Jena  
Table-Centrifuge Typ 5410      Eppendorf, Hamburg 
Tissue culture plastics     Greiner, Nürtingen 
Microscope LSM-Meta 510     Zeiss, Jena 
Microtome       Leica 
MP Hyperfilm       Amersham, Freiburg, Germany 
 
2.1.3 Kits 
 
Easy Pure DNA purification Kit Biozym Diagnostik GmbH, Oldendorf, Germany 
Qiagen Plasmid Maxi Kit   Qiagen, Hilden, Germany 
Zero® Blunt® TOPO PCR Kit  Invitrogen, Karlsruhe, Germany 
pcDNA 3.1+TOPO direct.clon. Kit Invitrogen, Karlsruhe, Germany 
 
2.1.4. Bacterial strains 
 
E.coli DH5α:  
Bacterial strain for plasmid expression 
Genotype: supE44∆lacU169 (ΦlacZ∆M15) hsdR7 recA1 gyrA96 thi-1 relA1 
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2.1.4.1. bacterial growth media 
 
Normal growth medium (Luria Broth, LB) : 
 Yeast extract 10g/L 
 NaCl    5g/L 
 Tryptone   5g/L 
pH 7.5 
 
Super Optimal broth with Catabolite repression (SOC): 
 Tryptone 2% 
Yeast extract 0.5% 
NaCl  10mM 
KCl  2.5mM 
MgSO4  10mM 
MgCl2  10mM 
Glucose  20mM 
 pH 7.4 
 
MgSO4, MgCl2 and KCL were sterile filtered and added after autoclavation.  
 
2.1.5. Tissue culture 
 
2.1.5.1. Cell lines 
 
Hela: 
Human Negroid cervix epithelial carcinoma 
ECACC No. 930210013 
 
Cos 7: 
Monkey African green kidney, SV-40 transformed 
ECACC No. 87021302 
 
NIH3T3: 
Murine embryonal fibroblast (Swiss mouse embryo). 
ECACC No. 93061524 
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NIH3T3 clone 2U 
 
Stable NIH-3T3 clones bearing an array of amplified uPA-Luc gene unit were obtained by Blasticidin 
selection after co-transfection of equimolar amounts of -1977/-1858uPA-TATA-Luc and p∆BN-AR1, 
which promotes an amplification of co-transfected plasmids (Shimizu et al, 2003). Copy number was 
estimated by real time PCR analysis, using primers amplifying both the Chinese hamster DHFR 
genomic region contained in p∆BN-AR1 and the endogenous mouse counterpart, as described 
(Bosisio 2006).   
NIH3T3 clone 7m 
 
Stable NIH-3T3 clones bearing an array of amplified MMTV-Luc gene unit generated like described 
above. 
 
NIH3T3 clone 12c 
 
Stable NIH-3T3 clones bearing an array of amplified Collagenase I minimal promoter-Luc gene unit 
generated like described above. 
 
2.1.5.2. Tissue culture conditions 
 
All cell lines were cultured at 6% CO2, 95% humidity, 37°C in an incubator. Manipulation of 
cells was performed under a sterile hood. Media, Buffers and glassware were sterilised before 
work (120°C, 1.4 bar, 20min). 
 
2.1.5.3. Cell line culture media 
 
 
 
 
Growth-medium 
10%DCS-DMEM 
Starvation-medium 
0,5%DCS-DMEM 
Growth-medium 
10%FCS-DMEM 
Starvation-medium 
0,5%DCS-DMEM 
Hela + + - - 
Cos-7 - - + + 
NIH3T3 + + - - 
2U + + - - 
7m + + - - 
12c + + - - 
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2.1.6. Enzymes 
 
Restriction-enzymes and buffers were used from the following companies: 
NEB  Frankfurt am Main, Germany 
Promega Mannheim, Germany 
Fermentas St. Leon-Rot, Germany 
 
2.1.7. Plasmids 
 
2.1.7.1. Mammalian expression vectors 
 
pcDNA 3.1(+) 
Empty vector, basic mammalian expression cloning vector. 
 
pcDNA 3.1(+) HA  
Contains the cDNA encoding for 8 amino acids of the haemaggluthinin protein, which was 
used to tag proteins (provided by Marga Litfin, ITG, FZKA Karlsruhe). 
 
pcDNA 3.1(+) HA-Trip6190-476 
Contains the cDNA of Trip6190-476 fused to a HA-tag. The start-codon is missing within the 
clone and was introduced via the marker. The construct was cloned via EcoRI/XoI (provided 
by Christine Heilbock, ITG, FZKA Karlsruhe). 
 
pcDNA 3.1(+) HA-Trip6190-476∆DD2 
Contains the cDNA of Trip6190-476 with a deletion of the second dimerisation-domain fused to 
a HA-marker. The start-codon is missing within the clone and was introduced via the marker. 
The deletion was introduced by a fusion PCR using the primer pairs Trip6190-476-forward 
KpnI:∆DD2-reverse and ∆DD2:Trip6190-476-reverse XbaI. The construct was cloned via 
KpnI/XbaI. 
 
pcDNA 3.1(+) HA -LIM 
Contains the cDNA encoding only for the LIM-domains of Trip6, fused to a HA-marker. The 
start-codon is missing within the clone and was introduced via the marker. The sequence was 
amplified by PCR using the primer pairs LIM-forward KpnI and Trip6190-476-reverse XbaI. 
The construct was cloned via KpnI/XbaI. 
 
pGAL4DBD 
Contains the cDNA for the DNA-Binding-Domain of the GAL4-yeast transcription factor 
under the control of a CMV-promoter (provided by Marga Litfin, ITG, FZKA Karlsruhe). 
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pGAL4DBD-Trip6 
Contains the cDNA of Trip6 fused to the DNA-Binding-Domain of the GAL4-yeast 
transcription factor under the control of a CMV-promoter (provided by Marga Litfin, ITG, 
FZKA Karlsruhe). 
 
pGAL4DBD- -LIM 
Contains the cDNA of Trip6 LIM-domains alone, fused to the DNA-Binding-Domain of the 
GAL4-yeast transcription factor under the control of a CMV-promoter (provided by Marga 
Litfin, ITG, FZKA Karlsruhe). 
 
pCGcJun~cFos  
Expression of cJun~cFos fusion under the control on CMV promoter. 
Described in Bakiri et al., 2002 
 
pCGcJun~ATF2  
Expression of cJun~ATF2 fusion under the control on CMV promoter. 
Described in Bakiri et al., 2002 
 
2.1.7.2. Expression vectors for fluorescent protein fusions 
 
pcDNA3.1(+)-HA-CFP 
Contains the cDNA for the cyan fluorescent protein (CFP) under the control of a CMV-
promoter, which is fused to a HA tag. Generated via PCR using pcDNA3.1-CFP (Invitrogen, 
Karlsruhe) as a template using the primer pair Cherry-forward NotI and Cherry-reverse XbaI 
and cloned into pcDNA 3.1(+)-HA via NotI/XbaI. 
 
pcDNA3.1(+)-HA-YFP 
Contains the cDNA for the yellow fluorescent protein (YFP) under the control of a CMV-
promoter, which is fused to a HA tag. Generated via PCR using pcDNA3.1-YFP (Invitrogen, 
Karlsruhe) as a template using the primer pair Cherry-forward NotI and Cherry-reverse XbaI 
and cloned into pcDNA 3.1(+)-HA via NotI/XbaI. 
 
pcDNA3.1(+)-HA-mCherry 
Contains the cDNA for the cherry-red fluorescent protein (mCherry, provided by Roger Y. 
Tsien, UCSD, La Jolla CA, USA) under the control of a CMV-promoter, which is fused to a 
HA tag. Generated via PCR using the primer pair Cherry-forward NotI and Cherry-reverse 
XbaI and cloned into pcDNA 3.1(+)-HA via NotI/XbaI. 
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pcDNA-3.1(+)-mCherry 
Contains the cDNA for the cherry-red fluorescent protein (mCherry, provided by Roger Y. 
Tsien, UCSD, La Jolla CA, USA)) under the control of a CMV-promoter. Generated via PCR 
using the primer pair Cherry-forward NheI and Cherry-reverse KpnI and cloned into pcDNA 
3.1(+)-HA via NheI/KpnI. 
 
pcDNA-3.1(+)-mOrange 
Contains the cDNA for the orange fluorescent protein (mOrange, provided by Roger Y. Tsien, 
UCSD, La Jolla CA, USA)) under the control of a CMV-promoter. Generated via PCR using 
the primer pair Cherry-forward NheI and Cherry-reverse KpnI and cloned into pcDNA 
3.1(+)-HA via NheI/KpnI. 
 
pcDNA-3.1(+)-mCherry-NLS-DD1 
Contains the cDNA of Trip6 dimerisation domain I fused to a nuclear localisation signal 
(NLS) of the SV-40 virus and the sequence of the cherry-red fluorescent protein (mCherry) 
under the control of a CMV-promoter. Generated via Oligocloning using primer pair DD1 for 
BamHI and DD1 rev XbaI and cloned into pcDNA 3.1(+) via BamHI/XbaI. 
 
pcDNA-3.1(+)-mCherry-NLS-DD1-Srambled  
Contains the scrambled cDNA of Trip6 dimerisation domain I fused to a NLS and the 
sequence of the cherry-red fluorescent protein (mCherry) under the control of a CMV-
promoter. Generated via Oligocloning using primer pair DD1-SCR for BamHI and DD1-SCR 
rev XbaI and cloned into pcDNA 3.1(+) via BamHI/XbaI. 
 
pcDNA-3.1(+)-mCherry-NLS-DD2 
Contains the cDNA of Trip6 dimerisation domain II fused to a NLS and the sequence of the 
cherry-red fluorescent protein (mCherry) under the control of a CMV-promoter. Generated 
via Oligocloning using primer pair DD2 for BamHI and DD2 rev XbaI and cloned into 
pcDNA 3.1(+) via BamHI/XbaI. 
 
pcDNA-3.1(+)-mCherry-NLS-DD2Scrambled 
Contains the scrambled cDNA of Trip6 dimerisation domain II fused to a NLS and the 
sequence of the cherry-red fluorescent protein (mCherry) under the control of a CMV-
promoter. Generated via Oligocloning using primer pair DD2-SCR for BamHI and DD2-SCR 
rev XbaI and cloned into pcDNA 3.1(+) via BamHI/XbaI. 
 
pcDNA3.1(+)-HA-Trip6190-476-CFP 
Contains the cDNA of Trip6190-476 fused to CFP. The construct was generated via PCR using 
the primer pair Trip6190-476 forward KpnI and Trip6190-476 reverse NotI and cloned into 
pcDNA3.1(+)-HA-CFP via KpnI/NotI. 
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pcDNA3.1(+)-HA-Trip6190-476-YFP 
Contains the cDNA of Trip6190-476 fused to YFP. The construct was generated via PCR using 
the primer pair Trip6190-476 forward KpnI and Trip6190-476 reverse NotI and cloned into 
pcDNA3.1(+)-HA-YFP via KpnI/NotI. 
 
pCMV-GFP-GR 
Expression of Glucocorticoid receptor fused to GFP under the control of CMV promoter 
(provided by Andrew Cato, ITG, FZKA Karlsruhe). 
 
pCMV-GFP-POLII 
Expression of RNA-Polymerase-II fused to GFP under the control of a CMV promoter. 
(provided by Kimihiko Sugaya, National Institute of Radiological Sciences Chiba, Japan). 
 
pCMV-cFos-Venus 
Expression of cFos fused to Venus under the control of a CMV promoter. 
(provided by Chang-Deng Hu, Purdue University School of Pharmacy, USA). 
 
pcDNA3.1(+) HA-GR-mCherry 
Contains the cDNA of the Glucocorticoid-receptor (GR) fused to mCherry. The construct was 
generated via PCR using the primer pair GR-VN forward KpnI and GR-VN reverse NotI and 
cloned into pcDNA3.1(+)-mCherry via KpnI/NotI. 
 
2.1.7.3. Expression vectors encoding for Bimolecular fluorescent complementation assay 
 
pBiFC-YC 
Composed of the pCMV-HA vector (Clontech); the coding sequence of aminoacids 155-238 
of the C-terminal part of the Yellow Fluorescent Protein (YFP) is cloned directly after the 
multiple cloning side (provided by Tom Kerppola, University of Michigan). 
 
pBiFC-YN 
Composed of the  pFLAG-CMV vector (Sigma); the coding sequence of aminoacids 1-155 of 
the C-terminal part of the Yellow Fluorescent Protein (YFP) is cloned directly after the 
multiple cloning side (provided by Tom Kerppola, University of Michigan). 
 
pBiFC–Trip6190-476-YC  
Containing the cDNA of Trip6190-476. It was amplified from a pcDNA 3.1(+)-HA-Trip6190-476 
vector via PCR using the primer pair Trip6190-476-YC for EcoRI and Trip6190-476-YC rev XhoI 
and cloned using EcoRI/XhoI. 
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pBiFC–Trip6190-476-LIM1m-YC  
Containing the cDNA of Trip6190-476 with a mutation within the two zinc-fingers of LIM-
domain 1 (replacement of cysteins  279,282,307,310 to alanine). It was amplified from a 
pcDNA 3.1(+)-HA-Trip6190-476 vector via PCR using the primer pair Trip6190-476-YC for 
EcoRI and Trip6190-476-YC rev XhoI and cloned using EcoRI/XhoI. 
 
pBiFC– Trip6190-476-LIM3m-YC  
Containing the cDNA of Trip6190-476 with a mutation within the two zinc-fingers of LIM-
domain 3 (replacement of cysteins 399, 402, 432, 435 to alanine). It was amplified from a 
pcDNA 3.1(+)-HA-Trip6190-476 vector via PCR using the primer pair Trip6190-476-YC for 
EcoRI and Trip6190-476-YC rev XhoI and cloned using EcoRI/XhoI. 
 
pBiFC–LIM-YC 
Containing the cDNA of Trip6227-476. It was amplified from a pcDNA 3.1(+)-HA-Trip6190-476 
vector via PCR using the primer pair LIM-YC for EcoRI and LIM-YC rev XhoI and cloned 
using EcoRI/XhoI. 
 
pBiFC–Trip6190-476-YN 
Containing the cDNA of Trip6190-476. It was amplified from a pcDNA 3.1(+)-HA-Trip6190-476 
vector via PCR using the primer pair Trip6190-476-YN for HindIII and Trip6190-476-YN rev 
KpnI and cloned using HindIII/KpnI. 
 
pBiFC–cJun~cFos-YC 
Containing the cDNA of the fusionprotein cJun~cFos. It was amplified via PCR from 
pCGcJun~cFos vector and cloned via EcoRI/XhoI (provided by Sylwia Sekula, ITG, FZKA 
Karlsruhe).  
 
pBiFC–cJun~ATF2-YC 
Containing the cDNA of the fusionprotein cJun~ATF2. It was amplified via PCR from 
pCGcJun~ATF2 vector and cloned via EcoRI/XhoI (provided by Sylwia Sekula, ITG, FZKA 
Karlsruhe).  
 
pcDNA3.1(+)-HA-VN 
Composed of the pcDNA-3.1(+)-HA vector in fusion with the coding sequence of aminoacids 
1-172 of the N-terminal part of the Venus Fluorescent Protein (VN-CT), amplified by PCR 
using the primer pair VN-CT for NotI and VN-CT rev XbaI and cloned via NotI/XbaI. 
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pcDNA3.1(+)-HA-VC 
Composed of the pcDNA-3.1(+)-HA vector in fusion with the coding sequence of aminoacids 
155-238 of the C-terminal part of the Venus Fluorescent Protein (VC-CT), amplified by PCR 
using the primer pair VC-CT for NotI and VC-CT rev XbaI and cloned via NotI/XbaI. 
 
pcDNA3.1(+)-HA-Trip6190-476-VN 
Containing the cDNA of Trip6190-476. The construct was generated via PCR using the primer 
pair Trip6190-476 forward KpnI and Trip6190-476 reverse NotI and cloned into pcDNA3.1(+)-
HA-VN via KpnI/NotI. 
 
pcDNA3.1(+)-HA-Trip6190-476-VC 
Containing the cDNA of Trip6190-476. The construct was generated via PCR using the primer 
pair Trip6190-476 forward KpnI and Trip6190-476 reverse NotI and cloned into pcDNA3.1(+)-
HA-VC via KpnI/NotI. 
 
pcDNA3.1(+)-HA-LIM-VC 
Containing the cDNA of Trip6227-476. The construct was generated via PCR using the primer 
pair LIM forward KpnI and Trip6190-476 reverse NotI and cloned into pcDNA3.1(+)-HA-VC 
via KpnI/NotI. 
 
pcDNA3.1(+)-HA-Trip6190-476∆LIM-VC 
Containing the cDNA of Trip6190-476∆LIM. The construct was generated via PCR using the 
primer pair Trip6190-476 forward KpnI and Trip6190-476∆LIM reverse NotI and cloned into 
pcDNA3.1(+)-HA-VC via KpnI/NotI. 
 
pcDNA3.1(+)-HA-GR-VN 
Containing the cDNA of the Glucocorticoid-receptor (GR). The construct was generated via 
PCR using the primer pair GR-VN forward KpnI and GR-VN reverse NotI and cloned into 
pcDNA3.1(+)-HA-VN via KpnI/NotI. 
 
pcDNA3.1(+)-HA-cFos-VC 
Containing the cDNA of cFos. The construct was generated via PCR using the primer pair c-
Fos-VC forward KpnI and c-Fos-VC reverse NotI and cloned into pcDNA3.1(+)-HA-VC via 
KpnI/NotI. 
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pcDNA3.1(+)-VC 
Composed of the  pcDNA-3.1(+) vector in fusion with the coding sequence of the 155 
aminoacids of the N-terminal part of the Venus Fluorescent Protein (VC-CT), which is cloned 
directly after the multiple cloning side using the primer pair VC-NT-for NheI and VC-NT-rev 
KpnI via NheI/KpnI. 
 
pcDNA3.1(+)-VN 
Composed of the  pcDNA-3.1(+) vector in fusion with the coding sequence of the 175 
aminoacids of the N-terminal part of the Venus Fluorescent Protein (VN-CT), which is cloned 
directly after the multiple cloning side using the primer pair VN-NT-for NheI and VN-NT-rev 
KpnI via NheI/KpnI. 
 
pcDNA3.1(+)-VC-Trip6 
Containing the cDNA of Trip6. It was amplified from a pcDNA 3.1(+)-HA-Trip6 vector via 
PCR using the primer pair Trip6 forward KpnI and Trip6 reverse NotI and cloned using 
KpnI/NotI. 
 
pcDNA3.1(+)-VN-Trip6 
Containing the cDNA of Trip6. It was amplified from a pcDNA 3.1(+)-HA-Trip6 vector via 
PCR using the primer pair Trip6 forward KpnI and Trip6 reverse NotI and cloned using 
KpnI/NotI. 
 
2.1.7.4. Expression vectors to generate recombinant proteins 
 
pGEX-4T-1 
Basic cloning vector for the expression of recombinant proteins fused a GST-protein 
(glutathion-s-tranferase) (Promega, Mannheim) and expression in bacteria.  
 
pGex-4T1-Trip6190-476 
contains the cDNA of Trip6190-478, which is fused to GST, and ligated via EcoI/XhoI into 
pGEX-4T-3.  
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2.1.8. Antibodies 
 
 Isotype Concentration Company 
Human Trip6 BL443 Rabbit 1/100//1/1000 
IF       WB 
Bethyl 
Vinculin sc-5573 Mouse 1/250 Santa Cruz 
E-Cadherin #610181 Mouse 1/100 BD Bioscience 
anti-Flag M2 Clone F1804 Mouse 1/100 Sigma 
anti-HA Clone 3F10 Rat 1/100//1/1000 
IF         WB 
Roche 
anti –GST Clone GST-2 Mouse 1/500 Sigma 
anti -rat-Alexa 488 Goat 1/1000 Invitrogen 
anti -rat-Alexa 546 Goat 1/1000 Invitrogen 
anti -rabbit-Alexa 488 Goat 1/1000 Invitrogen 
anti -rabbit-Alexa 546 Goat 1/1000 Invitrogen 
anti -mouse-Alexa 488 Goat 1/1000 Invitrogen 
anti -mouse-Alexa 546 Goat 1/1000 Invitrogen 
Phalloidin Rhodamine  1/1000 Molecular Probes 
DRAQ5  1/1000 Biostatus Limited 
anti -goat HRP Rabbit 1/1000 Dako 
anti -mouse HRP Goat 1/1000 Dako 
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2.1.9. Primer used for amplification and cloning into expression vectors 
 
Insert Sequence 
Trip6-forward KpnI 
Trip6-reverse NotI 
Trip6-reverse XbaI 
GGTACCTCGGGGCCCACCTGGCTG 
GCGGCCGCCTCAGCAGTCAGTGGTGACGGT 
TCTAGATCAGCAGTCAGTGGTGACGGT 
nTrip6-forward KpnI 
nTrip6-reverse NotI 
GGTACCCTGAATGGGGGTCGGGGTC 
ATTGCGGCCGCGGCAGCAGTCAGTGGTGACGGTGGC 
Trip6190-476-forward KpnI 
Trip6190-476-reverse NotI 
GGTACCCAGGCCTCTGGGCCCCTC 
GCGGCCGCCTCAGCAGTCAGTGGTGACGGT 
LIM-forward KpnI 
Trip6-reverse NotI 
GGTACCGGAGAAGATGTGGTTGGGGATGGGGCTGG 
GCGGCCGCCTCAGCAGTCAGTGGTGACGGT 
CFP/YFP-forward NheI 
CFP/YFP-reverse NotI 
GCGGCTAGCATGGTGAGCAAGGGCGAGGAG 
GCGGGTACCCTCGTACAGCTCGTCCATGCCGAGAGTG 
Cherry/Orange/Tomato-
forward NheI 
Cherry/Orange/Tomato-reverse 
KpnI 
GCGCTAGCATGGTGAGCAAGGGCGAGGAGCTG 
 
GCGGTACCACCGGATCCTCCACCTCCGCCTGAGCCCTTGTACAGCTCGTCC 
Cherry/Orange/Tomato-
forward NotI 
Cherry/Orange/Tomato-reverse 
XbaI 
GCGGCCGCGGCTCAGGCGGAGGTGGAGGATCCGGTGTGAGCAAGGG 
 
GCTCTAGATAACTTGTACAGCTCG 
VN-NT-forward NheI 
VN-NT-reverse KpnI 
GCGCTAGCATGGTGAGCAAGGGCGAGGAGCTG 
GCGGTACCACCGGATCCTCCACCTCCGCCTGAGCCCTCGATGTTGTGGCGG 
VC-NT-forward NheI 
VC-NT-reverse KpnI 
GCGCTAGCATGGACAAGCAGAAGAACGGCATCAAGGCC 
GCGGTACCACCGGATCCTCCACCTCCGCCTGAGCCCTTGTACAGCTCGTCC 
VN-CT-forward NotI 
VN-CT-reverse XbaI 
GCGGCCGCGGCTCAGGCGGAGGTGGAGGATCCGGTGTGAGCAAGGG 
GCTCTAGACTACTCGATGTTGTGGCGG 
VC-CT-forward NotI 
VC-CT-reverse XbaI 
GCGGCCGCGGCTCAGGCGGAGGTGGAGGATCCGGTGACAAGCAGAAGAACG 
GCTCTAGATAACTTGTACAGCTCG 
NES-for KpnI 
NES-rev BamHI 
GGTACCCCTACAAAAGAAGCTAGAAGAACTAGAACTAGAA 
GGATGTTTTCTTCGATCTTCTTGATCTTGATCTTGGATCC 
NLS-for KpnI 
NLS-rev BamHI 
GGTACCCCCAAAGAAGAAGCGAAAGGTA 
GGGTTTCTTCTTCGCTTTCCATGGATCC 
GR-VN-for KpnI 
GR-VN-rev XbaI 
GCGGTACCATGGACTCCAAAGAATCATTAAC 
AAAGCGGCCGCGCTTTTGATGAAACAGAAGTTTTTTG 
Trip6190-476-YC-for EcoRI 
Trip6190-476-YC-rev XhoI 
CGAATTCGGCAGGCCTCTGGGCCCCTCCCG 
ACCTCGAGAGCAGTCAGTGGTGACGGTGGC 
LIM-YC-for EcoRI 
LIM-YC-rev-XhoI 
CGAATTCGGGGCCAGTGTGGTGGCTGCGGA 
ACCTCGAGAGCAGTCAGTGGTGACGGTGGC 
Trip6190-476-YN-for HindIII 
Trip6190-476-YN-rev KpnI 
AAGCTTCAGGCCTCTGGGCCCCTCCCG 
TGGTACCGAGCAGTCAGTGGTGACGGTGGC 
Trip6190-476∆LIM-reverse NotI CTCGAGAAAAGTACTCCCCGCTGGGCGG 
c-Fos-for VC KpnI 
c-Fos-for VC NotI 
GCGGTACCTTCTCGGGTTTCAACGCCG 
GCGCGGCCGCCAGGGCCAGCAGCGTGGG 
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2.2. Methods 
 
2.2.1. DNA-Methods 
 
2.2.1.1. DNA digestion via restriction-endonucleases 
 
2-3 units of restriction-endonuclease were used per µg DNA. The total volume of the digest 
was 10 times the volume of the enzyme/glycerol-solution. Additionally a 10-times 
concentrated buffer-solution was added to the DNA-enzyme mix in order to achieve the 
required milieu for the enzyme. The DNA-enzyme-buffer mix was incubated, if not 
recommended differently by the supplier, for at least 2h at 37°C. 
 
2.2.1.2. Ligation of DNA-fragments 
 
Ligation reactions were performed using T4 DNA ligase according to manufacturer’s 
instructions (Fermentas). 
 
2.2.1.3. Polymerase chain reaction (PCR) 
 
By using two sequence-specific oligonucleotides DNA-fragments  were amplified by using 
the thermo-stable Pfu-DNA-polymerase. The reaction was carried out in a Perkin-Elmer-
Thermo-Cycler (Norwalk, USA). 
 
 
PCR Mixture:      PCR-Program  
     
10xPCR buffer   5µl  1cycle:   
DMSO    5µl   5min 94°C 
0.1µg template DNA  1µl  35cycles:  
forward primer    10mM  1µl   1min  95°C 
reverse primer 10mM  1µl   1min  55° 
10mM dATP   1µl   xmin  72°C (depending on size of fragment) 
10mM dCTP   1µl  1cycle:  
10mM dGTP   1µl   hold at  4°C 
10mM    dTTP   1µl     
Pfu-DNA polymerase  0.25µl     
H2O       _________ 
                                                add 50µl     
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For screening a large number of bacterial clones, the PCR was modified to perform a “colony-
PCR”. Here, a bacterial clone was picked with a small pipette-tip a directly passed over into 
the PCR-reaction mixture and then the tip was further passed into LB or SOC containing 
selection-markers (e.g. Ampicilin or Kanamycin). 
Instead of the Pfu-DNA-polymerase the faster GoTaq-polymerase from Promega was used 
due to its capability to amplify 1kb/minute. 
 
PCR Mixture:      PCR-Program  
     
10xPCR buffer   5µl  1cycle:    
bacterial colony   0µl   5min 94°C  
forward primer    10mM  0.5µl  35cycles: 
reverse primer 10mM  0.5µl   1min  95°C 
10mM dATP   0.5µl   1min  55° 
10mM dCTP   0.5µl   xmin  72°C (depending on size of fragment) 
10mM dGTP   0.5µl  1cycle: 
10mM    dTTP   0.5µl   hold at  4°C  
Taq-DNA polymerase  0.25µl     
H2O       _________ 
                                                add 25µl  
 
The PCR-reactions were then loaded on a 1%-2% agarose-gel, according to expected 
fragment size, to analyse the fragment length. 
 
2.2.1.4. Electrophoresis via agarose-gels 
 
Depending on fragment size, agarose-gels were cast at a concentration between 0,8-2%. 
Between 50ml and 400ml of gel solution depending on chamber size was used and covered 
with a layer of buffer (between 100ml and 1000ml). The agarose was dissolved in 1xTAE 
(40mM Trips pH 8,3; 40mM NaAzetate; 2mM EDTA pH8,0) buffer and melted in a 
microwave oven. Afterwards the glass-beaker was cooled down by running water and 
ethidium bromide was added to the gel-solution. Finally it was poured into the chambers 
equipped with a comb and cooled down to room temperature. The solid gel was covered with 
1x TAE-buffer, the comb was removed and the samples (10mM EDTA; 10% Glycerol; 0,1% 
SDS; 0,02% Bromphenol blue) were loaded. The separation was achieved by applying 
voltage between 80-120V. DNA could be visualized by UV-light (302nm) and was 
photographed for documentation.  
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2.2.1.5. Isolation of DNA-fragments out of agarose gels 
 
Fragments corresponding to DNA of interest were cut out of the agarose-gel at the UV-table 
with a scalpel and transferred onto parafilm for “freeze-squeeze” or into an Eppendorf-
reaction tube for kit-based elution (Promega) according to manufacturers’ protocol. 
 “freeze-squeeze”: 
Excised DNA-fragments were transferred to -20°C till they were completely frozen. 
Afterwards the frozen gel pieces were packed into parafilm and squeezed by hand. The 
extracted solution containing the DNA was collected in a Eppendorf-reaction tube. The DNA 
was precipitated in 100%EtOH, 1/40 of total volume 3M NaAc followed by a centrifugation 
step, 12k rpm, 4°C, 15min. The pellet was then washed in 70% EtOH followed by a 
centrifugation step, 12k rpm, 4°C, 15min. then the DNA was dried at room temperature till no 
EtOH was left and dissolved in 50µl TE-buffer (10mM Tris-HCL; 1mM EDTA pH 8,0).  
 
2.2.1.6. ”Mini-Preparation”/small-scale preparation of plasmid-DNA 
 
This technique was applied to screen bacteria-clones for DNA-content after transformation of 
a ligated vector. The bacteria-clone was put into 2ml LB containing an antibiotic selection 
marker (e.g. Ampicilin, Kanamycin,…) and was cultivated over night in a shacking incubator 
at 37°C. Next day 1.5ml of this culture was transferred into an Eppendorf reaction tube and 
centrifuged (3500rpm, 4°C, 3min). The supernatant was removed and the pellet was 
resuspended  in 200µl ice-cold TELT-buffer (50 mM Tris-HCl pH 8,0, 62,5 mM EDTA, 2,5 
M LiCl, 0,4% Triton X-100) followed by administering 20µl Lysozyme (10 mg/ml in TE-
Buffer (10 mM Tris-HCl, 1 mM EDTA pH 8,0)). This mix was then incubated for 3min on a 
heating block at 96°C, transferred onto ice for 5min, and centrifuged (12000 rpm, 4°C, 
15min). After centrifugation the supernatant, which is containing the DNA, was mixed with 
100µl Isopropanol, vortexed and centrifuged again (12000rpm, 4°C, 15min). The DNA pellet 
was washed with 1ml 70% EtOH and dried at room temperature. Afterwards it was dissolved 
in 50µl 1xTE-buffer (10mM Tris-HCL; 1mM EDTA pH 8,0). 
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2.2.1.7. ”Maxi-Preparation”/large-scale preparation of plasmid-DNA 
 
LB-medium containing an antibiotic selection marker was inoculated with a bacteria-clone 
selected via “mini-preparation” or with bacteria directly transformed with DNA of interest 
and transferred to a shacking incubator till next day at 37°C, shaking. The preparation was 
performed according to manufacturers protocol (Qiagen).  
The precipitated DNA was washed again with 70%EtOH. The DNA pellet was dissolved in 
100-400µl 1xTE-buffer and quantified.  
 
2.2.1.8. Estimation of DNA-concentration 
 
DNA concentration within aqueous solutions was estimated by spectra photometry. An OD of 
1 measured at 260nm corresponds to 50µg/ml double-stranded DNA or 40µg/ml single-
stranded RNA. To estimate the purity of the sample, OD at 280nm was measured. At this 
wavelength phenol, ethanol and proteins lead to a shift in the spectra. The ration OD260/OD280 
should be ideally ~1,8 for DNA and ~2,0 for RNA. 
 
2.2.2. Generating chemically competent bacteria 
 
A single colony of E. coli DH5α was incubated in 5ml LB medium overnight at 37°C with 
shaking (200 rpm). The 4 ml were used to inoculate 400 ml of fresh LB medium and allowed 
to grow to an OD600 of 0.4. After chilling on ice for 10 min the cells were centrifuged at 
3600g for 10 min at 40C. The pellet was re-suspended in 20 ml of ice cold 0.1M CaCl2 and 
allowed to stand on ice for 10 min. Then bacteria were centrifuged once more and again re-
suspended in CaCl2. This procedure was repeated once more. Finally the pellet was re-
suspended in 2 ml of ice-cold CaCl2 with 10% glycerol. After 5 min incubation on ice, the 
bacteria were aliquoted and frozen at -80°C. 
 
2.2.3. Transformation of chemically competent E.coli bacteria 
 
2.2.3.1. Transformation of ligated vector-DNA or vector DNA 
 
Chemical transformation was used for propagation of plasmids and DNA ligation products. 
1µl plasmid DNA or 2-7µl of a ligation mix was added to 100µl ice-thawed chemically 
competent E.coli. After mixing and incubation on ice for 15 min bacteria were heat-shocked 
at 42°C for 30 sec and incubated on ice for another 2 min. The transformed bacteria were 
mixed with 0,5ml of SOC medium and incubated at 37°C with shaking for 1h. Finally the 
bacteria were plated onto the LB agar plates supplemented with appropriate antibiotics for 
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selection and allowed to grow for 16-24h at 37°C or directly transferred into 100ml LB 
containing the appropriate antibiotics and allowed to grow for 12-24h at 37°C. 
 
2.2.3.2. TOPO-Cloning 
 
Topo-cloning is the direct ligation of PCR products in vectors, and was carried out according 
to manufacturers manual. 
 
2.2.4. Protein-methods 
 
2.2.4.1. Measurement of protein content according to Bradford 
 
5µl of protein containing solution was mixed with 200µl Bradford-solution and transferred 
into a 96well flat-bottom plate. This well was afterwards placed in an ELISA-plate reader and 
protein content was estimated via extinction at 660nm. The total protein concentration in the 
samples was interpolated from a bovine serum albumine (BSA) standard curve.  
 
2.2.4.2. Separation of proteins via a polyacrylamide gel electrophoresis (SDS-Page) 
 
Protein samples (2x sample buffer: 125mM Tris-HCL pH 6,8 ;4% SDS; 20% Glycerol; 0,01% 
Bromphenolblue; 2% 2-Mercapthoethanol) were electrophoretically separated on the basis of 
the size using the method from Laemmli (1970). The resolving gels containing between 8-
12% acryl amide depending on experiment and 5% stacking gel (6-12% Acrylamid; 0,16-
0,32% N,N´-Methylenbisacrylamide; 375mM Tris-HCL pH 8,8; 0,1% APS; 0,1% TEMED) 
were cast according to Sambrook et al. (1989). Samples were run into the stacking gel 
(running buffer: 25mM Tris; 192mM Glycin; 0,1% SDS) at 60-80V and then run at 100-140V 
in the separating gel (4% Acrylamid; 0,1% N,N´-Methylenbisacrylamide; 125mM Tris-HCL 
pH 6,8; 0,1% APS; 0,1% TEMED) with a mini gel system (Hoefer, San Francisco, USA). 
 
2.2.4.3. Coomassie-brilliant-blue stain of proteins 
 
To stain and visualize proteins separated by SDS-page the gel was incubated with a 
Coomassie-brilliant-blue staining solution (0,25% Coomassie-brilliant-blue R250; 50% 
Methanol; 10% Acetic acid) for 1h at room temperature followed by a destaining step in 
destain solution I (50% Methanol; 10% Acetic acid ) 1-2h followed by  destain solution II 
(5% Methanol; 7% Acetic acid ) over night. Destaining was carried out till protein bands 
appeared. The gel was then dried via a gel-drier. 
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2.2.4.4. Western blotting 
 
Proteins in SDS-PAGE gels were transferred (20mM Tris; 192mM Glycine; 10% Methanol) 
to methanol soaked Immobilon-P membranes in a semi-dry blotter at 1mA/cm2 for 1h. After 
the transfer membranes were incubated in blocking buffer (5% skimmed milk powder; TBS ) 
room temperature for 1h to reduce unspecific binding. Primary antibodies were diluted in 
blocking buffer at concentration recommended by the supplier (generally 1:500-1:3000). 
Membranes were incubated in the primary antibody-containing buffer for 1-2h at room 
temperature or overnight at 4°C. The membranes were then washed three times with TBST 
buffer ((TBS: 20mM Tris; 150mM NaCl; pH 7,6)+ 0,05% TWEEN 20) for 5 minutes each. 
With appropriate horse radish peroxidase (HRP) conjugated 2dary antibody diluted in blocking 
buffer membranes were incubated for additional 1h at room temperature. Membranes were 
washed again with TBST buffer for three times. Detection of specific protein signals were 
achieved using enhanced chemiluminescence (ECL) Western blotting detection reagents and 
ECL Hyperfilm following manufacturer’s instructions. 
 
2.2.4.5. Production of Glutathion-S-Transferase-fusion proteins 
 
By fusing eukaryotic proteins to the protein Glutathion-S-Transferase (GST) from 
Schisostoma japonicum they can be produced in high amounts and soluble states. The cDNA 
of the protein of interest was fused by cloning into the vector pGEX-4T-1 directly after the 
3´end of the GST coding sequence. The affinity of GST to glutathione allows to purify the 
fusion protein under mild conditions via affinity-chromatography by using immobilized 
glutathione.  
80ml of a stationary pre-culture of a transformed bacteria-strain was diluted 1:10 in LB 
containing an appropriate antibiotic and incubated at 37°C till an OD600 of 0,6 was reached. 
The protein expression was induced by adding IPTG and by addition of 10µM ZnSO4 Zinc 
Finger-containing proteins were stabilised.  Protein production was carried out for 4h at 30°C. 
Afterwards the bacteria were transferred onto ice for 10 min then pelleted via centrifugation 
(3000 rpm, 4°C, 15 min). The supernatant was discarded and the pellet resuspended in 8ml 
ice-cold fusionproteinbuffer.  
All following steps were carried out on ice: 
The bacteria and the bacteria-DNA were mechanically sheared by sonifying the solution. The 
insoluble bacterial components were then separated from the soluble fraction containing the 
proteins by ultracentrifugation (25000g, 4°C, 45 min). Glutathione immobilized on agarose 
beads was stored in 20% Ethanol. 1ml of this 1:1 solution mix was washed twice shortly 
before use in PBS. The supernatant of the ultracentrifuged bacteria was poured onto the beads 
and incubated for 45min at 4°C under constant rotation. The beads were washed 3 times with 
fusion protein buffer. Thereafter the bead-protein mix was transferred into a column and the 
fusion protein was eluted fractionwise from the agarose-beads by adding 5mM Glutathion 
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(dissolved in 50mM Tris-HCL) and collected in Eppendorf-reaction tubes. The protein of 
each fraction was measured via Bradford, and the fusion proteins were detected by SDS-page 
followed by a Coomassie-brilliant-blue staining of the acrylamide-gel. 
The fusion proteins were dialysed against PBS over night at 4°C using Dialyses-hoses and 
stored at -80°C until usage. 
 
2.2.4.6. in vitro protein-protein interaction studies – Spot®-Technique 
 
This system is based on the specific synthesis of peptides in a single position (spot) on a 
cellulose-membrane. Depending on the format of this membrane several different peptides 
could be spotted parallel. Peptide synthesis on the membrane was performed fully automatic 
by a robot under the supervision and control of Claudia Ester (ITG, FZKA, Germany). After 
synthesis of the selected peptide-sequences they were subjected to interaction studies by 
incubation of the membrane with proteins of interest. 
 
After finishing the production process, the peptides immobilized on the membrane were used 
as baits to investigate their interaction with recombinant expressed GST-fusion-proteins. 
In a first step, the membrane was activated by placing it in 100% methanol for 10min and 
rinsed 3 times in TBS for 5min. Afterwards the membrane was transferred into a blocking 
buffer-solution for 3h to reduce unspecific binding of primary antibody followed by washing 
the membrane in TBS for 5min. That was followed by incubation with a recombinant 
expressed fusion protein (10µg/ml in blocking buffer), which should be observed for 
interaction with Trip6 protein sequence. Incubation was carried out by adding GST-Trip6190-
476 over night at 4°C. Next day the membrane was washed 3 times with TBS to get rid of 
unbound protein and incubated for 3h with an α-GST-antibody (diluted 1:1000 in blocking 
buffer) at room temperature followed by washing steps, 3 times TBS-T, 5min, and incubated 
with a appropriate secondary antibody coupled to Horse-reddish peroxidase (HRP; diluted 
1:5000 in blocking buffer) for 1½ h. After washing the membrane 3 times with TBS-T, 
proteins interacting with the spotted peptide-sequences were highlighted via a enhanced 
chemiluminescence ECL Western blotting detection reagents and ECL Hyperfilm following 
manufacturer’s instructions. 
 
2.2.5. DNA-Pulldown 
 
This pulldown-assay using a biotinylated DNA-template as bait allows to investigate the 
composition of protein-complexes recruited to a known DNA template. For my studies, I used 
a template generated by PCR containing a TRE (TPA-responsible element), a TATA-box and 
a part of the luciferase gene coding sequence. This construct mimics a promoter area with all 
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necessary binding sites to allow AP-1 to bind and to recruit co activator complexes and the 
basal transcription factor machinery.  
 
2.2.5.1. Preparation of nuclear extracts 
 
2x106 logarithmically growing HeLa-cells were seeded in a 15cm dish in 10% DCS 
containing D-MEM and incubated over night at 37°C. Next day the medium was changed and 
cells were starved with 0.5% DCS D-MEM for 24-48h. Normal medium contains growth 
factors which lead to the activation of AP-1. Therefore the starvation leads to the reduction of 
already present AP-1. Only after stimulation at a given time point with TPA AP-1 is activated 
and leads to the activation of all other factors necessary for activating transcription of AP-1 
target genes. After that starvation time cells were stimulated with the phorbol ester TPA for 
4h at 37°C to activate AP-1. Cells were washed 3 times with ice cold PBS-/-,scraped in 1ml 
PBS-/- with a rubber-blade cell scraper, and pelleted by centrifugation (1200rpm, 3min, 4°C). 
The supernatant was discarded and cells were washed in 5 times pellet-volume of hypotonic 
lysis buffer (10mM HEPES KOH pH 7,9; 1,5mM MgCl2; 10mM KCl; add PIC; 0,5mM DTT) 
followed by resuspension in 3 times cell pellet volume of hypotonic lysis buffer, and allowed 
to swell on ice for 10min. Swollen cells were then disrupted on ice in a douncer (10-15 
strokes). The cell lysate was then centrifuged to pellet the nuclei (4000rpm, 4°C, 15 min). The 
nuclei pellet was resuspended in ½ nuclei pellet volume of low salt extraction buffer (20mM 
HEPES KOH pH 7,9; 25% glycerol; 1,5mM MgCl2; 20mM KCl; 0,2mM EDTA; add PIC; 
0,5mM DTT). Then ½ nuclei pellet volume of high salt buffer (20mM HEPES KOH pH 7,9; 
25% glycerol; 1,5mM MgCl2; 1,2M KCl; 0,2mM EDTA; add PIC; 0,5mM DTT) was added 
dropwise, and nuclear proteins were extracted by incubation at 4°C for 30min under constant 
rotation. The extracted nuclei were ultracentrifuged (15000rpm, 4°C, 30min). The supernatant 
containing nuclear proteins was then dialysed in dialysis-cassettes (Thermo scientific) against 
DNA-pulldown buffer (DPD; 20mM HEPES KOH pH 7,9; 10% glycerol; 50mM NaCl; 5mM 
MgCl2; 0,5mM EDTA; 0,1% NP-40; add PIC; 0,5mM DTT) over night at 4°C. Next day the 
dialysed protein solution was collected and protein content was measured using Bradford and 
stored until usage at -80°C. 
 
2.2.5.2. Preparation of biotinylated DNA template 
 
The biotinylated DNA fragment was generated by PCR using the Collagenase-I-promoter-Luc 
vector. The forward primer of the PCR to generate the DNA-template was ordered 
biotinylated at its 5´end. Due to this, the bait can be coupled to streptavidin.  
 
 
 
 
2. Material and Methods 
38 
Template-preparation via PCR: 
 
PCR Mixture:      PCR-Program  
     
5xPCR buffer   4µl  1cycle:    
DMSO    1µl   5min 94°C  
forward primer biotin   10mM 1,5µl  40 cycles: 
reverse primer 10mM  1µl   1min  95°C 
10mM dNTP   0,45l   1min  55° 
Taq-DNA polymerase  0.25µl    xmin  72°C (depending on size of fragment) 
Template CollI-Luc  0,1µg  1cycle: 
H2O       _________   hold at 4°C 
                                                add 25µl  
 
To purify the PCR by electrophoresis a sufficient amount of the 180bp bait fragment, 40-50 
PCR reactions were pooled and loaded on a 2% agarose-gel. The bait fragment was purified 
by the “freeze-squeeze” method. The biotinylated DNA-template was dissolved in 50µl 
1xTE-buffer, and concentration was estimated by comparing with a DNA of known 
concentration followed by a semi-quantitative gel electrophoresis. 
 
2.2.5.3. DNA pulldown 
 
50µg nuclear extracts were mixed together with 100ng of biotinylated DNA template, 100ng 
of salmon sperm DNA, to block unspecific binding to DNA, in DPD containing 0,5mM DTT 
in a total volume of 100µl. The reaction was incubated for 20min at room temperature under 
constant rotation. The biotinylated DNA bait and the bound proteins were captured by 
magnetic beads coupled to streptavidin (Dynabeads) blocked by incubation with digested 
BSA to reduce unspecific binding of proteins. 
 
BSA-digest: 
0,5g of BSA were dissolved in 10ml 50mM NH4CO3  and denatured for 10min at 95°C. Then 
10mg/ml trypsin was added to the solution and incubated at 37°C over night to digest the 
BSA. To check if the digest was complete, 1mg of digested BSA was loaded on a 10% 
acrylamide-gel and after electrophoresis stained with coomassie-brilliant blue. Undigested 
BSA would lead to a signal at ~70kDa, digested BSA can not be visualized with Coomassie-
brilliant-blue. 
 
Afterwards 10µl of pre-blocked streptavidin-Dynabeads were added to the mix and incubated 
for 30min at 4°C under mild rotation to allow the magnetic beads the capture of the 
biotinylated DNA and associated protein complexes. The magnetic beads were washed using 
a magnet and washing was performed by soaking for 5 times in 0,5ml of DPD at 4°C. The 
2. Material and Methods 
39 
pulled down protein complexes were harvested by adding 30µl 2x sample buffer and boiling 
for 5 min at 95°C, separated from the beads by centrifugation, and separated by SDS-PAGE 
on a 8% or 12% acrylamide gel to resolve high-molecular and low-molecular proteins, 
respectively. 
To visualize the separated proteins, a modified silver staining protocol was used, which 
allows a characterization of the proteins by MALDI-TOF. 
 
Modified Silverstain-protocol: 
The acrylamide-gels were first fixed twice by transferring in 10% acetic acid, 40% ethanol for 
15min at room temperature. Then the gels were sensitized by incubating with 250ml 
sensitizing solution (75ml Ethanol; 10ml Na-thiosulphate (5%); 17g Na-acetate (250ml 
ddH2O)) for 30min at room temperature. After sensitizing, the gels were washed 3 times for 5 
min each in 250ml ddH2O and the silver solution (25ml silver nitrate (2,5%; 250ml 
ddH2O))was added for 20min. After washing the gels twice in ddH2O for 1min each the 
staining was developed by adding a developer solution (6,25g Na-carbonate; 100µl 
formaldehyde (add250ml ddH2O)) for 4-5min at room temperature. The developing reaction 
was stopped by exchanging the solution with a stop solution (3,65g EDTA in 250ml ddH2O). 
Finally the gels were washed 3 times with ddH2O for 5min each and gels could then be 
scanned, bands excised and stored at 4°C. 
 
2.2.6. Tissue culture methods 
 
2.2.6.1. Passaging cells 
 
After removing the old tissue-culture media Trypsin-containing solution (2ml, 0,25% trypsin) 
was added to the cells and transferred to a incubator for 5min. Thereafter 10ml fresh medium 
was applied to the detached cells to stop trypsin-dependent digest and mixture was 
resuspended to separate cells. This mixture was administered to new Petri dishes according to 
the planned dilution. 
 
2.2.6.2. Seeding cells 
 
After removing the old tissue-culture media Trypsin-containing solution (2ml, 0,25% trypsin) 
was added to the cells and transferred to a incubator for 5min. Thereafter 10ml fresh medium 
was applied to the detached cells to stop trypsin-dependent digest and mixture was 
resuspended to separate cells. 
Thereupon cells were collected within a falcon-tube (15ml), centrifuged (1500 rpm, 5min), 
and the supernatant was removed. The cell-pellet was resuspended in 10ml fresh medium. 
To count cells per ml, 10µl were transferred to a Neubauer counting chamber. Cells were 
counted by using a brightfield-microscope. 
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2.2.6.3. Freezing and thawing of cells 
 
For freezing, logarithmically growing cells were trypsinised as described above and collected 
by centrifugation. Cells were resuspended in freezing medium (DMEM, 40%FSC, 
10%DMSO) and transferred into cryostatic tubes. After incubation on ice for 30 minutes, 
cells were slowly frozen at -80°C and then transferred to liquid nitrogen. For re-propagation 
cells were thawed quickly at 37°C and transferred to fresh medium. The next day medium 
was replaced with fresh cell culture medium. 
 
2.2.6.4. Transfecting cells 
 
Cells were seeded 24h before transfection into dishes or plates with a cell number according 
to the surface. 
 
 Surface in cm2 HeLa Cos-7 NIH3T3 
10cm 55 2x106 - - 
6well 9,4 5x105 1x105 - 
12well 3,8 3x105 - - 
24well 1,9 1x105 5x104 - 
96well 0,4 1x104 5x103 - 
8well chamber slide 0,95 1,5x104 5x103 1,5x104 
 
Transfection cells using Lipofectamin2000 (Invitrogen): 
According to 8-well-chamber slide 
 
In a 1.5ml Eppendorf-reactiontube 25µl D-MEM without serum were provided and the 
calculated amount of DNA was added (max. 200ng).  
After the preparation of all samples Lipofectamin2000 was added into a separated vessel 
(15ml falcon-tube or 1,5ml Eppendorf reactiontube depending on total number of 
transfections), mixed with D-MEM (25µl/well) and incubated 3min at room temperature. The 
amount of Lipofectamin2000 to use is dependent on the amount of DNA and cell line. Next 
step was the mixture of DNA-D-MEM with Lipofectamin2000-D-MEM. 25µl of the 
transfectionagent D-MEM mix was administered to the DNA mix and inverted several times 
to mix properly. This mixture was then incubated 15min at room temperature. 
In the mean time the growing medium was changed and fresh prewarmed medium was 
applied onto the cells. 
After incubation the DNA-transfection reagent-mixture was applied onto the cells and 
transferred again to the incubator. 
After 5h incubation the medium was changed again and replaced by fresh growing medium. 
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Transfection cells using FuGENE6 (Roche): 
According to 8-well-chamber slide 
 
In a 1.5ml Eppendorf-reactiontube 12,5µl D-MEM without serum were provided and the 
calculated amount of DNA was added (max. 200ng).  
After the preparation of all samples FuGENE6 was added into a separated vessel (15ml 
falcon-tube or 1,5ml Eppendorf reactiontube depending on total number of transfections), 
mixed with D-MEM (12,5µl/well). The amount of FuGENE6 to use is dependent on amount 
of DNA and cell line. Next step was the mixture of DNA-D-MEM with FuGENE6-D-MEM. 
12,5µl of the transfectionagent D-MEM mix was administered to the DNA mix and inverted 
several times to mix properly. This mixture was then incubated 30-45min at room 
temperature. 
In the mean time the growing medium was changed and fresh pre-warmed medium was 
applied onto the cells. 
After incubation the DNA-transfectionagent-mixture was applied onto the cells and 
transferred again to the incubator. 
 
2.2.6.5 Inducing cells 
 
UV irradiation: the medium was collected; cells were washed with PBS -/- and irradiated with 
40J/m2 UV-C light; the collected medium was poured back on cells. 
Dexamethasone (DEX): after starvation of cells DEX (10-6M) was added to the medium. 
Stock of DEX (10-2M) is stores at -20°C in EtOH. 
Phorbol ester (TPA): after starvation TPA was added to medium to final concentration 
50ng/ml. Stock of TPA (200µg/ml) is stored at -20°C. 
 
2.2.6.6. DNA-fluorescent in situ hybridisation (DNA-FiSH) 
 
Fixation and denaturing: 
Cells were seeded and cultured on glass coverslips (1,5cm ∅, Roth, Germany), then fixed by 
incubating with 8% paraformaldehyde for 30 min at room temperature. Cells were then 
washed 3 times in PBS(-/-) for 10 min each, and permebealized for 10 min in 0.5%Triton x-
100 in PBS(-/-) and washed again in PBS(-/-). Cells were then incubated with 50µg/ml 
RNAse for 60 min and then washed 3x for 10 min with PBS(-/-). Denaturing of DNA was 
achieved by incubating the coverslips at 95°C for 5min in presence of 50% formamid/2xSSC, 
then for 5min on ice in 50%formamide/2xSSC. The cells were then dehydration for 5min 
each in 70, 90 and 100% ethanol on ice. 
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Probe preparation and hybridisation: 
As a probe a fragment of luciferase coding sequence was amplified by PCR: 
A dUTP conjugated to Alexa 546 (Chromatide dUTP, Molecular Probes/Invitrogen) was 
incorporated into the PCR reaction to fluorescently label the PCR product. After gel-
purification the probe was dissolved in 140µl ddH2O, denatured by addition of 100µl 
formamide and heated for 10 minutes at 70°C. The probe was chilled in iced water and 160µl 
of 2,5x hybridisation solution (5xSSC,25%Dextran, 2,5mg/ml tRNA) was added. The 
fluorescent probe was stored until used at -20°C. 
 
Primers: 
Forward: TCTACTGGTCTGCCTAAAGG 
Reverse: AAACATTCCAAAACCGTGAT 
 
PCR Mixture:      PCR-Program  
     
10xPCR buffer   5µl   1cycle:   
25mM MgCl2   3µl   5min 94°C 
1ng/µl template DNA  1µl   5min 55°C 
forward primer    10mM  1µl   30cycles: 
reverse primer 10mM  1µl   2min  72°C 
10mM dATP   1µl   1min  94°C 
10mM dCTP   1µl   1min 55°C 
10mM dGTP   1µl   1cycle: 
2mM    dTTP   3,75µl   5min  72°C   
1mM Chromatide dUTP  2,5µl   hold at  4°C 
GoTaq®DNA polymerase 2,5U 
H2O       _________ 
                                                add 50µl     
 
Hybridisation: 
 
20µl of hybridisation solution containing the fluorescent probe was deposited on a glass slide 
and the cover slips with the cells were inverted onto the solution and incubated in the dark 
over night at 37°C. On next day, cells were washed with 2xSSC,0,05%Triton-X100 for 
10minutes, 2xSSC for 10 minutes, 4xSSC for 5minutes and rinsed with PBS(-/-). Finally the 
cover slips were mounted on glass slides using an aqueous mounting medium (DAKO). 
 
2.2.6.7. Reporter gene assays 
 
2.2.6.7.1. Collagenase-I-Luciferase reporter assay 
 
1x105 logarithmically growing HeLa-cells were seeded in a 24well plate and grown 
overnight. The next day cells were transfected with Lipofectamine 2000 reagent in ratio 3µl of 
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transfection reagent to 1µg of DNA. 100-400ng of plasmid DNA and 50 ng of reporter DNA 
(-517/+63Coll-Luc) were used for transfection. After transfection cells were incubated for 20h 
before starvation in 0.5% DCS containing DMEM medium. The cells were pre-starved for 8h 
and then cells were not induced or induced with TPA (50ng/ml) over night. Next day cells 
were subjected to measurement. They were washed twice with ice cold PBS-/- and lysed on 
ice in 25µl of 1x lysis buffer (Promega) and after successful lyses the luciferase activity was 
measured. Measurements were performed on Luminescence Counter. 
 
2.2.6.7.2. Gal-Luciferase reporter assay 
 
1x105 logarithmically growing HeLa-cells seeded in a 24well plate. Day after seeding cells 
were transfected with Lipofectamine 2000 reagent in ratio 3µl of transfection reagent to 1µg 
of DNA. 100-400ng of plasmid DNA and 100 ng of reporter DNA (GAL4UAS-Luc) were 
used for transfection. After transfection cells were incubated for 20h before starvation in 
0.5%DCS containing DMEM medium over night. Next day cells were subjected to 
measurement. They were washed twice with ice cold PBS-/- and lysed on ice in 25µl of 1x 
lysis buffer (Promega) and after successful lyses the reporteractivity was measured. 
Measurements were performed on Luminescence Counter. 
 
2.2.6.7.3. Array cell lines 
 
1,5x104 logarithmically growing NIH3T3-2u, 7m or 12c-cells (or NIH3T3-parental cells as 
control) were seeded in a specific 96well plate, which is designed for luminometers. The cells 
can be directly lysed in these plates and subjected to measurement. Day after seeding cells 
were pre-starved for 8h and then cells were not induced or induced (clone 2u with 
TPA(50ng/ml) or UV-irradiated (40J/m2); clone 7m with Dexamethasone (final concentration 
of 10-6M); clone 12c with TPA (50ng/ml)) over night. Next day cells were subjected to 
measurement. They were washed twice with ice cold PBS-/- and lysed on ice in 25µl of 1x 
lysis buffer (Promega) and after successful lyses the reporteractivity was measured. 
Measurements were performed on Luminescence Counter. 
 
2.2.6.7.4. Inhibiting AP-1 function by blocking peptides 
 
1x104 logarithmically growing HeLa-cells seeded in a specific 96well plate, which is 
designed for luminometers. The cells can be directly lysed in these plates and subjected to 
measurement. Day after seeding cells were transfected with Lipofectamine 2000 reagent in 
ratio 3µl of transfection reagent to 1µg of DNA. 25-100ng of plasmid DNA encoding 
blocking peptides (pcDNA3.1(+)-mcherry-NLS-DD1 or mCherry-NLS-DD1SCR) and 25 ng of 
reporter DNA (-517/+63Coll-Luc) were used for transfection. After transfection cells were 
incubated for 20h before starvation in 0.5%DCS containing DMEM medium. The cells were 
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pre-starved for 8h and then cells were not induced or induced with TPA (50ng/ml) over night. 
Next day cells were subjected to measurement. They were washed twice with ice cold PBS-/- 
and lysed on ice in 25µl of 1x lysis buffer (Promega) and after successful lyses the 
reporteractivity was measured. Measurements were performed on Luminescence Counter. 
 
2.2.6.7.5. Reverse Crosstalk-inhibiting GR transcription factor activity through c-Fos 
 
1x105 logarithmically growing Cos-7-cells seeded in a 24well plate. Day after seeding cells 
were transfected with FuGENE6 reagent in ratio 3µl of transfection reagent to 1µg of DNA. 
100-400ng of plasmid DNA encoding for pcDNA-3.1(+)-HA-c-Fos, pCMV-p65-GFP and 
pCMV-p65-YFP, 20ng of pcDNA3.1(+)-HA-GR and 20 ng of reporter DNA (MMTV-Luc) 
were used for transfection. After transfection cells were incubated for 20h before starvation in 
0.5%FCS containing DMEM medium. The cells were pre-starved for 8h and then cells were 
not induced or induced with DEX (10-6M) over night. Next day cells were subjected to 
measurement. They were washed twice with ice cold PBS-/- and lysed on ice in 25µl of 1x 
lysis buffer (Promega) and after successful lyses the reporteractivity was measured. 
Measurements were performed on Luminescence Counter. 
 
2.2.6.7.6. Luciferase activity measurement 
 
The amount of expressed Photinus pyralis-luciferase (Firefly) was measured from the lysed 
cell extracts. 
24h-48h post transfection cells were washed twice in ice-cold PBS-/- followed by adding lysis 
buffer in a volume appropriate to the well size (e.g. 25µl in 96well-plate, 100µl in 24well- 
plate) and lysis was carried out for 15min at 4°C. After lysis, 25 µl of lysates were transferred 
into a white 96well plate and subjected to luciferase measurement in an automated 
luminometer (Perkin Elmer). The reaction buffer and substrate were injected automatically 
into each well (70µl/well reaction buffer, 20µl/well substrate). The luminescence was 
measured for 2 seconds.  
 
Luciferin stock solution:    1mM luciferin (0,28mg/ml) in Gly-Gly-buffer  
Luciferin reactionmix:    1:5 dilution of stock in Gly-Gly-buffer   
Gly-Gly-buffer:     25mM Gly-Gly; 15mM MgSO4; 4mM EGTA; pH 7,8 
Reaction-buffer:     1mM DTT; 2mM ATP in Gly-Gly-buffer 
Lysis-buffer:     1:5 Dilution of 5x passive lysis buffer (Promega) in ssH2O 
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2.2.6.8. in vivo protein-protein-interaction via bimolecular fluorescent complementation      
assay 
 
A system to study protein-protein interaction in living cells is the bimolecular fluorescence 
complementation (BiFC) (Hu et al., 2002; Hu et al., 2006). This assay is based on the splitting 
of the yellow fluorescent protein (YFP) into two parts, YC (C-terminal part of YFP) and YN 
(N-terminal part of YFP). These two parts do not spontaneously re-associate and do not 
fluoresce. By fusing YC and YN to two interacting proteins, the two halves of YFP are 
brought together, leading to complementation of the fluophore. The advantage of the BiFC 
system compared to other protein-protein interaction systems is that the localisation of the 
interaction can be monitored by microscopy.  
 
1. YFP-based BiFC (Hu et al., 2002) 
Cells were seeded with a density of 1.5x104 cells/well in NUNC-8-well chamber slides and 
grown overnight at 37°C. Then they were transfected with 150ng of vector-DNA fused to the 
N-terminal part of YFP (YN) alone or together with vector-DNA fused to the C-terminal part 
of YFP (YC). As a transfection control cells were co-transfected with pcDNA3.1+-mCherry 
or dsRed-mito (30ng/well). As a transfection reagent I used Lipofectamin2000 (Invitrogen) 
with a DNA:Lipofectamin2000 ratio of 1:3. After 5h the medium was changed. Next day cells 
were transferred into a 30°C incubator for two hours to allow the maturation of the 
complemented YFP-protein after interaction. Imaging was performed using a Zeiss LSM 510 
Meta in confocal multitracking mode.  
 
2. Venus-based BiFC (Hu et al., 2006) 
Cells were seeded with a density of 1.5x104 in NUNC-8-well chamber slides and grown 
overnight at 37°C. Then they were transfected with 750ng of vector-DNA fused to the N-
terminal part of Venus (VN) alone or together with vector-DNA fused to the C-terminal part 
of Venus (VC). As a transfection control cells were co-transfected with pcDNA3.1+-mCherry 
(15ng/well). As a transfection reagent I used Lipofectamin2000 (Invitrogen) with a 
DNA:Lipofectamin2000 ratio of 1:3. After 5h the medium was changed. Next day cells were 
directly subjected to microscopy using a Zeiss LSM 510 Meta in confocal multitracking 
mode. 
 
2.2.6.9. Fluorescence resonance energy transfer (FRET) 
 
This protein-protein interaction assay is also termed Förster resonance energy transfer, named 
after the scientist Theodor Förster. FRET describes an energy transfer mechanism between 
two chromophores or fluorescent proteins. A donor chromophore in its excited state can 
transfer energy by a nonradiative mechanism to an acceptor chromophore in close proximity 
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(<10nm or <100Å). The energy transfer is analogous to a near field radio, because the radius 
of interaction is much smaller than the wavelength of light used. The excited atom emits a 
virtual photon which is accepted by the receiving atom. The recipient or acceptor 
chromophore is excited emits light with a shift in wavelength compared to the wavelength of 
the emitted light from the donor, reflecting the close proximity of the two interaction partners 
during a protein-protein interaction, (Piston and Kremers, 2007).  
To study the dimerisation of nTrip6 in living cells, I used Trip6190-476 fused to CFP as a FRET 
donor, and Trip6190-476 fused to YFP as an acceptor. Cells were seeded with a density of 
1.5x104 cells/well in NUNC-8-well chamber slides and grown overnight at 37°C. Then they 
were transfected with 100ng of Trip6190-476 fused to CFP alone, with Trip6190-476 fused to YFP 
alone or transfected together. As a transfection reagent I used Lipofectamin2000 (Invitrogen) 
with a DNA:Lipofectamin2000 ratio of 1:3. After 5h the medium was changed. Next day cells 
were directly subjected to microscopy using a Zeiss LSM 510 Meta in confocal multitracking 
mode (see Results section for details).  
 
2.2.6.10. Immunofluorescence 
 
 1. Antibody staining of adherent cells 
Cells seeded and cultured on glass-coverslips (1,5cm ∅, Roth, Germany) were fixed with 
3,7% Formalin in PBS-/- directly added onto cells for 10 min at room temperature followed 
by permeabilisation in 0,5% Triton X-100 in PBS for 5min. Cells were then washed 3 times 
with PBS-/- for 10 min. To avoid unspecific binding, cells were blocked with 
1%BSA/1%Goat-serum in PBS-/- for 30min. Antibodies diluted in blocking buffer (1g 
BSA/1ml goat serum in 100ml PBS-/-), were deposited on parafilm and the cells were 
incubated for 1h with the antibodies by inverting coverslips onto the antibody drop. 
The coverslips were collected using forceps and transferred into a 24 well plate for washing 
steps. Cells were washed 3 times in PBS-/- for 5 min. 
The appropriate secondary fluorescent labelled antibody was added for 30 min and then 
washed as described for the primary antibody. 
Finally coverslips were mounted in polyvinylalcohol (PVA: 20% Polyvinyl alcohol (Vinol 
205); 80ml PBS-/-) onto a glass slide. Images were taken with a Zeiss (Oberkochen, 
Germany) LSM510meta in confocal multitracking mode using a x63/ -oil lens. 
 
 2. Antibody-staining to study array-occupancy of NIH3T3 2U cells 
This procedure is similar to antibody staining of adherent cells except fixation. Cells were 
fixed by adding 8% PFA (8 g Paraformaldehyd in 100 ml H2O at 60°C and adding 1M NaOH 
until solution is clear and PFA-powder completely dissolved) directly onto cells still in 
culture medium (final concentration PFA: 4%) for20 min at room temperature. 
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3. Results 
 
Trip6 is described as a cytosolic protein, enriched at focal adhesions and at cell-cell contacts 
(Wang et al., 1999; Wang and Gilmore, 2001; Yi and Beckerle, 1998). This is illustrated by 
the Trip6 immunofluorescence-staining (Fig. 12), where focal adhesions were stained with an 
anti-Vinculin antibody and cell-cell contacts by an anti-E-Cadherin. 
 
 
 
 
 
 
 
 
 
 
Our group identified nTrip6, a shorter isoform of Trip6, presumably lacking the nuclear 
export signal (NES), and thus exclusively present in the nucleus. At the time of this work, the 
exact nature of nTrip6 was not known. I therefore used Trip6190-476 as a tool (Kassel et al., 
2004). This protein is shorter in size, lacks the NES and is thus exclusively nuclear (Fig. 13), 
and is fully functional to regulate AP-1 activity (Kassel et al., 2004).  
 
 
 
 
 
 
 
 
 
 
An HA-tagged version of Trip6190-476 is exclusively expressed in the nucleus, whereas HA-
Trip6 is only cytosolic, as shown by immunofluorescence staining (Fig. 13). 
 
 
 
 
 
 
c 
Fig.13: Subcellular localisation of Trip6
and nTrip6 
HeLa-cells were transfected with expression 
vectors for Trip6 fused to HA (HA-Trip6) or 
with HA fused Trip6190-476 (HA-Trip6190-476). 
Cells were then stained with an HA specific 
antibody and the nuclei were counterstained 
with DRAQ5. 
Trip6 is detectable in the cytosol, whereas 
Trip6190-476 is localised exclusively in the 
nucleus. 
 
b) a) 
    anti-HA   DRAQ5           merge 
HA-Trip6 
HA-
Trip6190-476 
Fig.12: Trip6 colocalizes with Vinculin, a marker 
for focal adhesions and E-Cadherin, marker for 
cell cell contacts 
HeLa were fixed and stained with a Trip6-specific 
antibody together with an antibody against Vinculin or 
E-Cadherin, and nuclei were counterstained using 
DRAQ5.  
a) anti-Trip6 (green) and anti-Vinculin (red); DRAQ5 
(nuclear marker, blue)  
b) anti-Trip6 (green) and anti-E-Cadherin (blue) 
An overlap between nTrip6 and DRAQ5 can be 
observed within the nucleus as well as an overlap 
between Trip6 and Vinculin at focal adhesion sites 
and Trip6 and E-Cadherin at cell-cell contac sites. 
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3.1. nTrip6 is a specific co-activator for c-Fos containing AP-1 dimers 
 
To investigate the co-activator function of nTrip6 for AP-1, I co-transfected HeLa cells with 
the AP-1-dependent -517/+63CollI-Luc reporter gene and increasing amounts of Trip6190-476 , 
and monitored the transcriptional activity after activation of AP-1 by treatment of the cells 
with the phorbol ester TPA.  
 
                   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When I co-transfected HeLa cells with increasing concentrations of Trip6190-476, in untreated 
conditions the reporter showed only a weak expression (Fig. 14). This basal level indicates 
low amounts of AP-1 present under unstimulated conditions. Treating cells with TPA resulted 
in a 20 fold increase in reporter activity. This activation was further increased in a dose 
dependent manner by co-transfection of increasing concentrations of Trip6190-476 (Fig. 14). 
This illustrates the already documented (Kassel et al., 2004) co-activator function of nTrip6 
for AP-1. 
 
3.1.1. nTrip6 interacts exclusively with AP-1 dimers containing Fos-family members  
 
At the start of this work, unpublished results of our group showed that over-expression of 
nTrip6 was not able to increase the transcriptional activity of the c-Jun:ATF2 AP-1 dimer. 
AP-1 is a transcription factor family composed of dimers of members of the Jun, Fos and 
CREB/ATF family. Is nTrip6 a common co-activator for all family members or is it limited to 
a certain dimer composition? As a first step to address this question, I investigated the 
interaction of nTrip6 with two typical AP-1 dimers c-Jun:c-Fos and c-Jun:ATF2. Both dimers 
are activated by different pathways and bind to dimer specific responsive elements in the 
Fig.14: nTrip6 functions as a co-activator for AP-1 
1,5x105 logarithmically growing HeLa-cells were 
transfected with the AP-1 regulated  
-517/+63CollI-Luc reporter gene together with
increasing amounts of Trip6190-476. 24h post 
transfection the cells were serum-starved with 0,5% 
DCS-DMEM and were induced overnight by 
treatment with TPA to induce AP-1. Next day cells 
were lysed and subjected to Luciferase reporter assay.
Results are presented as fold induction, and are the 
mean ± SD of a representative experiment performed 
in triplicates. 
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vicinity of their target genes. c-Jun:c-Fos binds to the heptameric TPA responsive elements 
(TRE) whereas cJun:ATF2 recognizes an octameric CREB-responsive element (CRE). To 
investigate the interaction between nTrip6 and these dimers, I used single chain AP-1 dimers, 
c-Jun~c-Fos and c-Jun~ATF2, provided by Latifa Bakiri (Bakiri et al., 2002). In these 
constructs c-Jun is linked to c-Fos or ATF2 by a flexible linker. Due to this tethering c-Jun 
dimerisation capacity is limited to its fusion partner. This ensures that any measured 
interaction is really via the studied dimer, and not due to c-Jun dimerising with endogenous 
AP-1 family members. 
A system to study protein-protein interaction in living cells is the bimolecular fluorescence 
complementation (BiFC) (Hu et al., 2002; Hu et al., 2006). This assay is based on the splitting 
of the yellow fluorescent protein (YFP) into two parts, YC (C-terminal part of YFP) and YN 
(N-terminal part of YFP). These two parts do not spontaneously re-associate and do not 
fluoresce. By fusing YC and YN to two interacting proteins, the two halves of YFP are 
brought together, leading to complementation of the fluophore. The advantage of the BiFC 
system compared to other protein-protein interaction systems is that the localisation of the 
interaction can be monitored by microscopy.  
 
To study the interaction between nTrip6 and the different dimer pairs, I designed fusion 
proteins composed of Trip6190-476 C-terminaly fused to YN and cJun~cFos as well as 
cJun~ATF2 fused to YC. To investigate if the expression and localisation of the fusion 
proteins was proper, I transfected HeLa-cells with these constructs and performed an antibody 
staining against the HA or the FLAG epitope also encoded in the construct.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cJun~ATF2-YC 
cJun~cFos-YC 
Trip6190-476-YN 
α−ΗΑ DRAQ5 merge
α−FLAG DRAQ5 merge
Fig. 15: BiFC-fusion of 
Trip6190-476 and the 
single chain AP-1 
dimers does not hamper 
proper localisation 
HeLa cells were 
transfected with Trip6190-
476 fused to the N-terminal 
part of YFP (YN), with 
cJun~cFos or cJun~ATF2 
fused to the C-terminal 
half of YFP (YC) and 
probed with an antibody 
against the HA- or FLAG-
tag. The nuclei of live 
cells were stained with 
DRAQ5 and fluorescent 
images were acquired by 
confocal microscopy.  
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Immunoreactivity was detectable within the nucleus of transfected cells (Fig. 15), showing 
that the fusion of Trip6190-476 to YN as well as the fusion of the single-chains c-Jun~c-Fos and 
cJun~ATF2 to YC did not hamper the localisation of the protein. I then used these constructs 
to investigate by BiFC the protein-protein interaction between nTrip6 and the two 
prototypical AP-1 dimers in living cells (Fig. 16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The complementation of YFP was observed in the nucleus of 70 to 80% of cells co-
transfected with equal amounts of the single chain c-Jun~c-Fos fused to YC and Trip6190-476 
fused to YN. No complementation was detected between c-Jun~ATF2-YC and Trip6190-476-
YN, although the cells were efficiently transfected, as judged by the expression of the cherry-
red fluorescent protein mCherry, which served as a transfection control (Fig. 16). This result 
shows that nTrip6 interacts with c-Jun~c-Fos, but not with c-Jun~ATF2 in living cells, 
confirming the results of in vitro experiments with individual AP-1 family members 
(Heilbock, 2004). 
 
We therefore conclude that nTrip6 is selectively interacting with AP-1 dimers containing Fos-
family members, and thus might be a selective co-activator for these AP-1 dimers. 
 
 
 
 
 
 
Flag- 
Trip6190-476-YN 
HA-cJ~cF-YC 
HA-cJ~A-YC 
         Compl.               mCherry                DRAQ5 
Fig. 16: nTrip6 selectively interacts with c-Fos containing AP-1 dimers  
HeLa cells were transfected with Trip6190-476 fused the N-terminal half of YFP (YN) together 
with either c-Jun~c-Fos YC or c-Jun~ATF2 fused to YC. As a transfection control cells 
were co-transfected with mCherry and nuclei were highlighted by DRAQ5. 16h post 
transfection cells were imaged using a laser scanning confocal microscope. 
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3.1.2. Recruitment of nTrip6 to AP-1 dependent promoter in a dimer specific fashion 
 
If nTrip6 is a selective co-activator for certain AP-1 dimers, it should be selectively recruited 
to promoters of target genes together with the AP-1 dimer. 
To directly visualize nTrip6 recruitment, I used a reporter cell line containing an integrated 
array of multiple copies of the -1977/-1858uPA-Luc reporter gene generated in our lab. This 
part of the uPa gene contains both a CRE and a TRE, and can be activated by both, c-Jun:c-
Fos and c-Jun:ATF2. The array was generated by transfecting the reporter plasmid together 
with the p∆BN-AR1 plasmid (Shimizu et al., 2003). p∆BN-AR1 contains a mammalian 
replication initiation origin and a matrix attachment region from the Chinese hamster dhfr 
gene: when integrated into the genome, it initiates events similar to gene amplification in 
cancer cells, leading to tandem repeats of up to 10 000 copies (Shimizu et al., 2003; Shimizu 
et al., 2001).  
The high local concentration of binding sites on the promoter of the amplified gene unit 
enables the direct visualization of binding to the gene array of proteins tagged with a 
fluorescent marker, as previously shown for an NF-κB-dependent array cell line (Bosisio et 
al., 2006). Using this amplification method NIH-3T3 fibroblasts carrying several hundred 
integrated uPA-Luc plasmid copies in discrete loci were obtained (Fig. 17). One of the cell 
clones, clone 2U, was shown by real-time PCR to harbour an integrated gene-array of about 
2000 gene units (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
The presence of the uPA-Luc gene-array was confirmed by DNA fluorescent in situ 
hybridization (FiSH) using a fragment of the luciferase coding sequence as a probe. The 
staining was detectable as a single spot within the nucleus of the 2U cells, and was present in 
100% of the cells, whereas only background staining was visible in the parental NIH-3T3 
cells (Fig. 17). 
Fig. 17: DNA fluorescence in situ hybridisation (DNA-Fish) highlights the uPA-Luc gene-
array 
Clone 2U and parental NIH-3T3 fibroblasts were subjected to DNA in situ hybridization using a 
fluorescently labeled cDNA probe complementary to the luciferase coding sequence. A single 
gene array is visible in 100% of the 2U cells. 
 
NIH3T3 
 
2U blowup 
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To investigate if the gene array was functional, clone 2U cells were subjected to different 
stimuli: either a treatment with TPA to activate c-Jun:c-Fos (Angel et al., 1988b) or UV-
irradiation to activate c-Jun:ATF2 (Adler et al., 1995; Adler et al., 1996), and the reporter 
gene activity was measured. 
  
 
 
 
 
 
 
 
 
 
Both TPA treatment and UV irradiation induced luciferase activity in clone 2U (Fig. 18), 
suggesting that both c-Jun:c-Fos and c-Jun:ATF2 are able to bind to their cognate response 
elements on the array and to activate transcription from the uPA-Luc gene array. 
 
The next step to confirm the functionality of the array was to study the recruitment of the two 
AP-1 dimers to the array, and their ability to mediate the recruitment of the RNA polymerase 
II (Pol II) to the array (Fig. 19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Over-expression of an HA-tagged version of the c-Jun~c-Fos single chain construct led to its 
recruitment to the array, as shown by the enrichment to a single bright spot in the nucleus 
after immunostaining with an anti-HA antibody. Furthermore, c-Jun~c-Fos mediated the 
Fig. 19: AP-1 is functionally 
recruited to the uPA 
promoter-array 
2U cells were transfected with
GFP-Pol II, together with the 
empty vector (Vector), an 
expression vector for an HA-
tagged c-Jun c-Fos single chain 
(HA-c-J c-F), or an expression 
vector for an HA-tagged c-Jun
ATF2 single chain (HA-c-J A). 
The localization of the AP-1 
single-chain proteins was 
determined by 
immunofluorescence using an 
anti-HA antibody. The 
enrichment of the AP-1 proteins 
and of GFP-Pol II was observed 
in 70–80% of the co-transfected 
cells. 
    HA    GFP-Pol II          overlay 
Vector 
HA-c-J~cF 
HA-c-J~A 
Fig. 18: The uPA-Luc gene array within clone 2U is functional 
1x104 logarithmically growing 2U-cells were seeded in a 96 well 
plate. 24h post seeding cells were serum-starved with 0,5% DCS-
DMEM and c-Jun:c-Fos was induced overnight by adding TPA, or c-
Jun:ATF2 was induced by UV-irradiation. Next day cells were lysed 
and subjected to Luciferase reporter assay. Results are presented as 
fold induction, and are the mean ± SD of a representative experiment 
performed in triplicates. 
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recruitment of Pol II to the array, as shown by the co-localization of the HA staining with 
GFP-Pol II (Fig. 19, overlay). Similarly, co-transfected HA-c-Jun~ATF2 and GFP-Pol II were 
co-recruited to the array. These specific enrichments to the array were observed in 70 to 80% 
of the transfected cells. GFP-Pol II was not enriched to the array when transfected alone, as 
shown by the homogenous nuclear fluorescence (Fig. 19). These results confirm that the uPA 
reporter gene array is functional and can respond to c-Jun:c-Fos and c-Jun:ATF2. 
The next question was: is nTrip6 recruited to the promoter together with c-Jun:c-Fos but not 
with c-Jun:ATF2? 
To investigate the recruitment of nTrip6 to the promoter I fused Trip6190-476 to the cyan 
fluorescent protein (CFP) or to YFP. I verified that the fusion to the fluorescent protein did 
not hamper the nuclear localisation by fluorescence microscopy (Fig. 20. a)). I also confirmed 
that the fusion to CFP or YFP did not interfere with the AP-1 co-activator function by 
performing a reporter gene assay using the AP-1 dependent -517/+63Coll-Luc reporter gene 
(Fig. 20. b)). 
 
     a)                                  b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In cells transfected with the -517/+63Coll-Luc reporter gene together with empty vector as a 
control treatment with TPA resulted in an increase in the reporter activity (Fig. 20. b)). When 
HA-tagged Trip6190-476 was co-transfected, the transcriptional activity of AP-1 was further 
increased, showing the co-activator function of nTrip6. Transfection of the cells with the 
fluorescent protein tagged Trip6190-476 led to the same extent to an increase in transcription 
activity (Fig. 20. b)). Thus, the fusion of CFP and YFP to Trip6190-476 did not change its 
capacity to function as a co-activator for AP-1 and made them suitable tools to investigate the 
recruitment of nTrip6 to different AP-1 promoters. 
Fig. 20: Fusion of nTrip6 to fluorescent proteins does not hamper its co-activator function 
1,5x105 logarithmically growing HeLa-cells were seeded in a 96 well plate and next day transfected with 
empty vector, Trip6190-476 fused to a HA-tag or Trip6190-476 fused to YFP or CFP. 24h post transfection cells 
were serum-starved with 0,5% DCS-DMEM and induced overnight by administration of TPA to induce AP-1. 
Next day cells were lysed and subjected to Luciferase reporter assay. Results are presented as fold induction. 
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I then studied the recruitment of nTrip6 to an AP-1 dependent promoter by co-transfection of 
the uPa-Luc array cell line clone 2U with Trip6190-476-YFP together with the single chains c-
Jun~c-Fos or c-Jun~ATF2 (Fig. 21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When transfected alone Trip6190-476-YFP showed a homogenous distribution in the nucleus, 
without specific local enrichment. Co-transfection with c-Jun~c-Fos resulted in a recruitment 
of Trip6190-476-YFP to the promoter array, whereas co-transfection with c-Jun~ATF2 did not 
(Fig. 21). GFP-Pol II was not enriched to the array when transfected alone, as shown by the 
homogenous nuclear fluorescence (Fig. 21). Upon co-transfection of the forced dimers Pol II 
was enriched at the gene array. These results confirm that the uPA reporter gene array is 
functional and can respond to c-Jun~c-Fos and c-Jun~ATF2. 
To summarize, nTrip6 interacts with c-Jun:c-Fos but not with c-Jun:ATF2, and is tethered to 
c-Jun:c-Fos, but not to c-Jun:ATF2 bound promoters. Together with the results showing that 
nTrip6 increases the transcriptional activity of only Fos-containing AP-1 dimers 
(Diefenbacher et al., 2008; Sekula, 2006), these results demonstrate that nTrip6 is a selective 
co-activator for Fos-containing AP-1 dimers. 
 
3.1.3. c-Jun:ATF2 is not trans-repressed by the glucocorticoid receptor 
 
The next question addressed in this work concerns the specificity of nTrip6 action in the 
repression of the different AP-1 dimers by GR (Sekula, 2006). The first step in the trans-
Fig. 21: nTrip6 is not tethered to c-Jun:ATF2 occupied promoter. 
2U cells were transfected with empty vector, an expression vector for c-Jun c-Fos single 
chain (cJ cF), or an expression vector for c-Jun ATF2 single chain (cJ A), together with 
an expression vector for GFP-Pol II and an expression vector for Trip6190–476 fused to YFP 
(YFP-Trip6190–476). Images were acquired by confocal microscopy. Nuclei of representative 
cells are shown. 
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repression of c-Jun:c-Fos by the GR is the tethering of the GR to the AP-1 bound promoter, 
via the interaction of GR with nTrip6. Since c-Jun:ATF2 does not mediate the recruitment of 
nTrip6 to the promoter, I hypothesise that GR cannot repress c-Jun:ATF2, because it cannot 
be tethered to the c-Jun:ATF2 bound promoter. To address this question, I studied the 
recruitment of GR to the uPa promoter in the array cell line, in the presence of c-Jun:c-Fos or 
c-Jun:ATF2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
In cells co-transfected with GFP-GR and empty vector, treatment with the synthetic 
glucocorticoid dexamethasone resulted in a homogenous distribution of GP-GR within the 
nucleus (Fig. 22, left). This result confirms that GR does not directly bind to the uPa-
promoter. When GFP-GR was transfected together with c-Jun~c-Fos, dexamethasone 
treatment resulted in the enrichment of GR in a single spot within the nucleus (Fig. 22, 
middle). This result illustrates the tethering of GR to c-Jun:c-Fos occupied promoters. In cells 
co-transfected with GFP-GR and c-Jun~ATF2, dexamethasone treatment did not result in a 
recruitment of GR to the array (Fig. 22, right). Thus, GR can not be recruited to c-Jun:ATF2 
bound promoters. 
These result led me to propose that the lack of repression of c-Jun:ATF2 by GR is due to the 
inability of this AP-1 dimer to interact with nTrip6, which is the platform for the tethering of 
GR to promoter bound c-Jun:c-Fos (Diefenbacher et al., 2008; Kassel et al., 2004). 
 
 
 
 
 
 
 
 
 
Vector HA-cJ~cF HA-cJ~A 
GFP-GR 
Fig. 22: GR is not tethered to c-Jun:ATF2 occupied promoter 
2U cells were transfected with empty vector, an expression vector for c-Jun c-Fos single 
chain (cJ cF), or an expression vector for c-Jun ATF2 single chain (cJ A), together with 
an expression vector for GR fused to GFP. Cells were treated with dexamethasone for 30 
min and imaged by confocal microscopy. Nuclei of representative cells are shown. 
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3.2. Role of nTrip6 in the repression of GR by AP-1 
 
Since nTrip6 behaves as a co-activator and is interacting with GR (Kassel et al., 2004) one 
could hypothesise that nTrip6 is also a co-activator for GR. Moreover, nTrip6 is essential for 
GR mediated trans-repression of c-Jun:c.Fos (Kassel et al., 2004). If nTrip6 is a co-activator 
for GR, is it also required for the repression of GR by AP-1 or NF-κB? 
 
3.2.1. nTrip6 functions as a co-activator for GR 
 
To investigate the possibility that nTrip6 is a co-activator for GR, I performed reporter gene 
assays using the mouse mammary tumor virus promoter long terminal repeat (MMTV) 
containing a glucocorticoid receptor responsive element (GRE) fused to luciferase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
In HeLa cells transfected with vector control no GR transcriptional activity was observed in 
untreated conditions (Fig. 23). After treatment with dexamethasone, GR was activated 
resulting in an increase in transcriptional activity. This activity was further increased in a dose 
dependent manner upon co-transfection of increasing amounts of Trip6190-476 (Fig. 23). Thus, 
as observed for AP-1 (Diefenbacher et al., 2008; Kassel et al., 2004), nTrip6 is able to 
increase the transcriptional activity of GR, suggesting that it might act as a co-activator for 
GR. 
I then investigated the interaction between nTrip6 and GR in living cells using the advanced 
BiFC-system based on the Venus fluorescent protein (Hu et al., 2006), a GFP derivate. If 
nTrip6 is a co-activator for GR, it should be recruited to GR regulated promoters through its 
interaction with GR. The first step was thus to confirm that nTrip6 interacts with GR in living 
cells. 
Fig. 23: nTrip6 increases GR-dependent 
transcription 
1,5x105 logarithmically growing HeLa-cells 
were transfected with increasing amounts of 
Trip6190-476 together with a GR dependent 
luciferase gene (MMTV-Luc). 24h post 
transfection the cells were serum-starved 
with 0,5% DCS-DMEM and treated with the 
synthetic glucocorticoid dexamethasone. 
Next day cells were lysed and subjected to 
Luciferase reporter assay. Results are 
presented as fold induction, and are the mean 
± SD of a representative experiment 
performed in triplicates. 
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I designed fusion proteins composed of Trip6190-476 C-terminaly fused to the C-terminal part 
of Venus (VC) and GR fused to the N-terminal part of Venus (VN) and verified that the 
fusion was not altering the localisation of the protein (Fig. 24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Trip6190-476 fused to VC was detectable within the nucleus of transfected cells (Fig. 24, lower 
panel). In untreated cells GR-VN was localized in the cytosol (Fig. 24, upper panel), only 
upon adding dexamethasone it translocated to the nucleus (Fig. 24, middle panel), showing 
that the fusion did not hamper GR translocation. The fusion of Trip6190-476 to the C-terminal 
part of Venus as well as the fusion of the glucocorticoid receptor to the N-terminal part of 
Venus did not hamper the localisation of the proteins. I then used the constructs to investigate 
GR interaction with nTrip6 in living cells (Fig. 25). 
 
 
 
 
 
 
 
 
 
 
 
 
 
In untreated cells co-transfected with GR-VN and Trip6190-476-VC, no complementation of the 
Venus protein was detected although cells were efficiently transfected as indicated by the 
Fig. 25: GR interacts with nTrip6 in living 
cells only in the nucleus  
HeLa cells were transfected with Trip6190-476
fused the C-terminal half of Venus  (VC)
together with GR fused to the N-terminal part 
of Venus (VN), and with mCherry fused to a 
nuclear export signal (NES) as a transfection 
indicator. 24h post transfection cells were 
imaged before and after 2h of dexamethasone 
treatment. Fluorescent images were acquired by 
confocal microscopy.  
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Fig. 24: BiFC-fusion of Trip6190-476
and the GR does not hamper their 
localisation  
HeLa cells were transfected with
Trip6190-476 fused to the C-terminal 
part of Venus (VC) or with GR 
fused to VN, treated with 
dexamethasone (10-6M) for 2h, and 
probed with an antibody against the 
HA-epitope and Phalloidin coupled 
to rhodamine to highlight the cell 
shape. The nuclei of cells were 
stained with DRAQ5 and 
fluorescent images were acquired by 
confocal microscopy.  
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expression of mCherry fused to a nuclear export signal (Fig. 25, left row). After treatment 
with dexamethasone, the complementation of Venus fluorescence was detectable. This 
complementation was exclusively observed in the nucleus of 70 to 80% of the transfected 
cells (Fig. 25, right row). 
Previous work of our group based on in vitro tecniques showed that GR was interacting with 
nTrip6 via the LIM-domain 3. To verify these results in living cells I generated VC-fusions of 
Trip6190-476 harbouring point mutations of the coordinating cysteins in the zinc fingers of the 
LIM-domains 1 and 3 (Trip6190-476-LIM1m-VC, Trip6190-476-LIM3m-VC). 
 
 
 
 
 
 
 
 
 
 
In cells transfected with Trip6190-476-LIM1m-VC or Trip6190-476-LIM3m-VC, the fusion 
proteins were detectable by immunofluorescene in the nucleus as indicated by DRAQ5 
staining (Fig. 26). Therefore the fusion of VC to the LIM-mutants did not hamper their proper 
localisation. I then used these constructs to study their interaction with GR in a BiFC 
experiment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 27: The Glucocorticoid receptor interacts with nTrip6 via LIM-domain 3 
HeLa cells were transfected with Trip6190-476-LIM1m-VC or Trip6190-476-LIM3m-VC together with GR
fused to VN, and with mCherry-NES as a transfection indicator. 24h post transfection cells were imaged 
before and after 2h of dexamethasone treatment. Fluorescent images were acquired by confocal 
microscopy.  
 
 
HA-Trip6190-476-
Lim1mVC 
HA-Trip6190-476-
Lim3mVC 
α-HA      Phalloidin     DRAQ5 Fig. 26: BiFC-fusion of Trip6190-476-LIM-
mutants does not hamper their nuclear 
localisation 
HeLa cells were transfected with Trip6190-476
harboring mutations within the LIM-
domains, LIM1m and LIM3m, fused to the 
C-terminal part of Venus (VC) and probed 
with an antibody against the HA-tag. The 
nuclei of cells were stained with DRAQ5 and 
fluorescent images were acquired by confocal 
microscopy.  
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No complementation was detectable in unstimulated cells transfected with Trip6190-476-
LIM1m-VC or Trip6190-476-LIM3m-VC together with GR (Fig. 27). After treatment with 
dexamethasone, the complementation of Venus was detectable in the nucleus of cells 
transfected with Trip6190-476LIM1m-VC together with GR-VN (Fig. 27). No complementation 
was observed in cells transfected with Trip6190-476LIM3m-VC together with GR-VN, although 
cells were efficiently transfected as illustrated by the expression of mCherry-NES (Fig. 27). 
 
This result shows that the activated GR is interacting with nTrip6 and that the interaction is 
mediated via the LIM domain 3.   
 
3.2.2. nTrip6 is recruited to GR-dependent promoters  
 
Thus, nTrip6 interacts with GR and enhances its transcriptional activity. If nTrip6 functions 
as a co-activator for GR, it should be recruited to the promoter of GR target genes in a GR-
dependent manner. 
To visualize the recruitment of nTrip6 in a living cell to a GR-dependent promoter I used 
another array cell line established in our group. This cell line, the clone 7m, was generated as 
described above for the uPA array cell line, using the MMTV-Luc reporter gene as a template 
for amplification and insertion. The presence of the gene-array was also visualized by DNA-
FiSH using a fragment of the luciferase coding sequence as a probe (Fig. 28). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Using this probe, the array was detectable in a single spot within the nucleus of the 7m cells, 
and was present in 100% of the cells, whereas only background staining was visible in the 
parental NIH-3T3 cells (Fig. 28). 
To investigate if the gene array was functional, cells were treated with dexamethasone to 
activate GR, and luciferase activity was measured (Fig. 29).  
 
 
Fig. 28: DNA fluorescence in situ hybridisation (DNA-Fish) highlights the 
MMTV-Luc gene array 
Clone 7m and parental NIH-3T3 fibroblasts were subjected to DNA in situ 
hybridization using a fluorescently labelled cDNA probe complementary to the 
luciferase coding sequence. A single gene array is visible in 100% of the 7m cells. 
7m blowup NIH3T3 
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Treatment of the parental cell line NIH3T3 with dexamethasone did not result in any 
detectable luciferase activity, as expected. The 7m clone showed a significant basal luciferase 
activity, which was strongly increased upon treatment of cells with dexamethasone (Fig. 29). 
This result shows that the array is functional. I therefore used this cell line to investigate 
whether nTrip6 is recruited together with GR on the promoter of target genes upon activation. 
I transfected the clone 7m with GFP fused RNA-Poll II to use the recruitment of Pol II as an 
indicator of the transcriptional activity of the gene array, with GFP fused GR or with Trip6190-
476-CFP. 
 
 
 
 
 
 
 
 
 
 
 
GFP-GR was located in the cytosol and upon dexamethasone treatment it translocated into the 
nucleus and was recruited to the array, as illustrated by the enrichment in a single locus within 
the nucleus (Fig. 30, left row). GFP-Pol II was not recruited to the array when GR was not 
active, but after treatment with the synthetic corticoid, RNA-Pol II was recruited to the array 
(Fig. 30, middle row). These enrichments were detectable in 70-80% of the transfected cells. 
These data further confirm that the array is functional and responds to glucocorticoids. 
Transfection of CFP-fused Trip6190-476 resulted in a homogeneous distribution in the nucleus 
of untreated cells. Upon treatment with dexamethasone Trip6190-476 was recruited to the array 
as indicated by an enrichment of Trip6190-476-CFP in a single spot in the nucleus (Fig. 30, right 
row). 
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Fig. 30: nTrip6 is recruited to a GR 
dependent promoter. 
7m cells were transfected with expression 
vectors for GFP-Pol II, GFP-fused GR or
Trip6190–476 fused to CFP (Trip6190–476-CFP).
Cells were imaged by confocal microscopy
before and 2h after treatment with 
dexamethasone.  
Fig. 29: The MMTV-Luc gene array in 
clone 7m is functional 
1x104 logarithmically growing 7m-cells as 
well as parental cells were seeded in a 96 
well plate. 24h post seeding cells were 
serum-starved with 0,5% DCS-DMEM and 
treated with the synthetic glucocorticoid 
dexamethasone. Luciferase activity was 
determined 16h later, and was plotted relative 
to the untreated NIH3T3 control cells. 
Results are presented as fold induction, and 
are the mean ± SD of a representative 
experiment performed in triplicates. 
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This result shows that nTrip6 is recruited to the promoter of GR target genes in a 
glucocorticoid dependent manner. 
However, if nTrip6 acts as a co-activator for GR, it should be recruited to the promoter via its 
interaction with GR. I therefore studied whether nTrip6 interacts with GR at the promoter 
upon activation using the advanced BiFC system in the array cell line. 
 
 
 
 
 
 
 
 
 
 
 
 
I co-transfected 7m cells with GR-VN and Trip6190-476-VC together with mCherry-NES as a 
transfection control. In the absence of dexamethasone no complementation of Venus was 
detectable in the nucleus of positively co-transfected cells, as expected (Fig. 31). Following 
treatment with glucocorticoids, complementation was observed in the nucleus, and this 
interaction between Trip6190-476 and GR was enriched at the array (Fig. 31).  
Thus, nTrip6 is recruited to activated GR-regulated promoters via its interaction with GR. 
This, together with the observation that nTrip6 increases GR transcriptional activity, 
demonstrates that nTrip6 functions as a co-activator for GR. 
 
3.2.3. nTrip6 mediates the trans-repression of GR by AP-1 
 
GR represses the transcriptional activity of AP-1 (Jonat et al., 1990). But on the other hand 
AP-1 is also able to interfere with the transcriptional activity of GR by trans-repressing GR 
(Schule et al., 1990).  
Since only Fos family members containing AP-1 dimers are trans-repressed by GR (see 
above) one could hypothesise that Fos plays a major role in GR repression by AP-1. To 
address this question, I studied the effect of over-expressing only Fos on GR-mediated 
transcription using the MMTV-Luc reporter gene construct. 
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Fig. 31: nTrip6 interacts with GR on the 
promoter. 
7m cells were transfected with an expression 
vector for GR fused to VN together with an 
expression vector for Trip6190–476 fused to VC.
As a transfection marker cells were co-
transfected with mCherry fused to a nuclear 
export signal. 24h post transfection, cells were 
imaged by confocal microscopy before and 2h 
after treatment with dexamethasone.  
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Cells only transfected with GR showed no expression of the reporter in unstimulated 
conditions (Fig. 32). Treatment with dexamethasone resulted in a strong reporter gene 
activity. By co-transfection of increasing amounts of c-Fos the transcriptional activity of GR 
was repressed, in a dose dependent manner (Fig. 32). This results shows that, as hypothesised, 
c-Fos alone is sufficient to trans-repress GR.  
 
In the repression of AP-1 by GR, nTrip6 interacting with c-Fos and GR, mediates the 
tethering of GR to the promoter-bound c-Fos. It therefore seemed logical to hypothesise that 
in the trans-repression of GR by AP-1, c-Fos is tethered to the promoter-bound GR via its 
interaction with nTrip6.  
To test this hypothesis, I co-transfcetd the MMTV gene array cell line 7m with c-Fos fused to 
Venus, GR fused to mCherry together with Trip6190-476 fused to CFP, and observed the 
recruitment of these proteins to the GR dependent promoter (Fig. 33). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 32: Overexpression of c-Fos inhibits 
GR trans-activation 
1x105 logarithmically growing Cos-7-cells 
were transfected with increasing amounts of 
c-Fos together with the MMTV-Luc, a 
reportergene regulated via GR. 24h post 
transfection the cells were serum-starved 
with 0,5% FCS-DMEM and treated with 
dexamethasone. Results are presented as fold 
induction, and are the mean ± SD of a 
representative experiment performed in 
triplicates. 
 
    Dex                  -                                                   +   
Fos-Venus            cherry-GR          Fos-Venus           cherry-GR 
Trip6190-476-CFP      merge           Trip6190-476-CFP         merge 
3. Results 
 
65 
 
 
 
 
In untreated co-transfected 7m cells GR was located in the cytosol, and c-Fos as well as 
Trip6190-476 showed a homogeneous distribution within the nucleus, without any visible 
enrichment. After treatment with dexamethasone GR translocated to the nucleus and was 
recruited to the array. nTrip6 was recruited to this array in a GR dependent manner as already 
shown. And at the same time c-Fos was also recruited to the array at which both nTrip6 and 
GR were located (Fig. 33). 
 
Thus, in repressing conditions, c-Fos interacting with nTrip6, is tethered to GR dependent 
promoters. 
 
In conclusion, nTrip6 is a common co-activator for GR and c-Fos containing AP-1 dimers. 
Additionally, nTrip6 is involved in the reciprocal crosstalk between these two transcription 
factors, by mediating the tethering of the repressing transcription factors to the promoter-
bound repressed transcription factor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 33(page before): nTrip6, c-Fos and GR co-localise at GR-dependent promoters 
7m cells were transfected with an expression vector for GR fused to mCherry together with an expression 
vector for Trip6190–476 fused to CFP and an expression vector for c-Fos fused to Venus. 16h post transfection, 
cells were imaged by confocal microscopy before and 2h after treatment with dexamethasone.  
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3.3. Mechanism of nTrip6 co-activator function 
 
nTrip6 exerts a co-activator function for AP-1, NF-κB and GR (Diefenbacher et al., 2008; 
Kassel et al., 2004). However, nTrip6 does not harbour any known co-activator domain or 
function. The only known functional domains of nTrip6 are the three LIM-domains, which 
mediate protein-protein interactions. We thus hypothesised, that nTrip6 exerts its co-activator 
function through the recruitment of other co-activators to the promoter of the target genes, 
through an interaction with the LIM-domains. 
 
3.3.1. The N-Terminus of nTrip6 is essential for its co-activator function 
 
To investigate via which part nTrip6 exerts its co-activator like function, I first studied 
whether the LIM-domains were sufficient, in an AP-1-dependent reporter gene assay. I 
transfected HeLa cells with different nTrip6 mutants together with the AP-1 dependent  
-517/+63Coll-Luc reporter gene (Fig. 34). On the one hand cells were co-transfected with 
Trip6190-476, on the other hand transfected with the LIM-domains alone, which are essential 
for the interaction with the transcription factors (Diefenbacher et al., 2008; Kassel et al., 
2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In cells transfected with vector control alone (V), treatment with TPA, which activates AP-1, 
resulted in an increase in reporter activity. When I co-transfect Trip6190-476, the transcriptional 
activity of AP-1 was further increased, illustrating the co-activator-like function of nTrip6. 
This increase was not seen after co-transfection with the construct expressing the LIM-
domains alone (Fig. 34). This result shows, that contrary to the hypothesis, the N-terminus of 
nTrip6 is essential for its co-activator function for AP-1. Furthermore, it suggests that the co-
activators might be recruited through an interaction with nTrip6 N-terminus. 
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Fig. 34: The N-terminus of nTrip6 is 
essential for its co-activator function  
1,5x105 logarithmically growing HeLa-cells 
were transfected with vector control (V), 
Trip6190-476 or LIM-domains (LIM123) alone.
24h post transfection cells were serum-
starved with 0,5% DCS-DMEM and treated 
witrh TPA to induce AP-1. Results are 
presented as fold induction, and are the mean 
± SD of a representative experiment 
performed in triplicates. 
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3.3.2. Co-activators are recruited via the LIM-Domains 
 
To confirm this result, I directly studied the autonomous co-activator function of nTrip6. To 
directly measure the ability of nTrip6 or of the LIM-domains alone to recruit co-activators to 
a promoter, they where fused to the DNA-binding domain of the yeast transcription factor 
GAL4 (GALDBD), transforming Trip6 into a pseudo-transcription factor. As a reporter gene I 
used Luciferase under the control of the GAL4-UAS, a promoter-region recognized by 
GALDBD. In this assay, nTrip6 is directly recruited to the promoter, without the need of 
protein-protein interactions via its LIM-domains. 
 
 
 
 
 
 
 
 
 
 
 
 
In cells transfected with vector control alone (V), only a weak transcriptional activity was 
observed. When I co-transfect Trip6190-476fused to GAL4DBD, the transcriptional activity was 
increased, showing the autonomous co-activator function of nTrip6. To my surprise, the same 
transcriptional activity was observed when cells were transfected with LIM-domains alone 
fused to GALDBD (Fig. 35) 
Thus, when nTrip6 is directly recruited to the promoter, its N-terminus is dispensable for its 
co-activator function, and the co-activators are recruited via the LIM-domains. 
 
3.3.3. nTrip6 forms homo-dimers 
 
There is a discrepancy in these results: on the one hand the N-terminus is essential for nTrip6 
function as a co-activator for AP-1 (Fig. 34), but on the other hand the N-terminus is 
dispensable for the autonomous co-activator function of nTrip6 (Fig. 35). 
 
One hypothesis, which could explain these apparent contradictory results, is that nTrip6 
dimerises through its N-terminus and that this dimerisation is essential for its co-activator 
function.  
LIM123 
Fig. 35: The N-Terminus of nTrip6 is dispensable 
for its autonomous co activator function  
1,5*105 logarithmically growing HeLa cells were 
seeded in  a 24 well plate and transfected next day 
with vector cxontrol (V), Trip6190-476 or LIM-domains 
(LIM123) fused to the Gal-DNA-binding -Domain 
(DBD) together with a GAL4-UAS driven luciferase 
reporter construct. Cells were harvested 16h later and 
luciferase activity was measured. Results are 
presented as fold induction, and are the mean ± SD of 
a representative experiment performed in triplicates. 
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To study this hypothesis I used the BiFC protein-protein interaction assay to investigate 
whether nTrip6 dimerises in living cells. Therefore I fused Trip6190-476 to the C-terminal and 
to the N-terminal part of YFP. 
I first investigated if the fusion proteins localise properly within transfected cells, by an 
antibody staining against the HA-tag encoded in the fusion protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
In cells transfected with empty vector alone (V), no specific signal was detectable, as 
expected. In cells transfected with either Trip6190-476 fused to YC or Trip6190-476 fused to YN, 
a specific staining was detectable in the nucleus, highlighted by staining with DRAQ5. 
Phalloidin rhodamine was used to illustrate the cell shape (Fig. 36). 
The fusion of Trip6190-476 to YC or YN did not hamper the proper expression nor the 
localisation of the protein. Thus I used the constructs to study the dimerisation of nTrip6 in a 
BiFC assay. 
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Fig. 36: Fusion of Trip6190-476 to YC 
or YN does not hamper its
localisation 
Cos-7 cells were transfected with
Trip6190-476 fused to the C-terminal 
part of YFP (YC) or to the N-terminal 
half of YFP (YN) and probed with an 
antibody against the HA-tag. 
Phalloidin conjugated to rhodamine 
was used to show the cellular 
shape.The nuclei of live cells were 
stained with DRAQ5 and fluorescent 
images were acquired by confocal 
microscopy.  
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Cells transfected with Trip6190-476-YN and with the empty vector encoding YC, together with 
dsRed-mito as a transfection marker, did not show any fluorescence complementation, 
showing that no spontaneous complementation of YFP was occurring (Fig. 37).  
After co-transfection of Trip6190-476-YC together with Trip6190-476-YN, a strong fluorescence 
was detected in the nucleus, highlighted by DRAQ5 staining. The complementation of YFP 
was observed in the nucleus of 70-80% of transfected cells, as judged by the expression of 
dsRed-mito. This result shows that nTrip6 dimerises, and this dimerisation occurs exclusively 
in the nucleus (Fig. 37). 
 
Since nTrip6 is the short isoform of the cytosolic protein Trip6 (Kassel et al., 2004) one could 
hypothesise that Trip6 dimerises as well, and this would occur in the cytosol. To answer this 
question, I generated BiFC-constructs based on the Venus fluorescent protein fusing VN and 
VC N-terminally to Trip6. To ensure that the fusion did not hamper the localisation of Trip6, 
cells were transfected with either Trip6 fused to VC or transfected with Trip6 fused to VN, 
and stained by using an antibody against the HA-Tag (Fig. 38). 
 
 
 
 
 
 
 
    Compl.   dsRed-mito   DRAQ5 
Trip6190-476-
YN 
+ 
YC 
Trip6190-476-YN 
+ 
Trip6190-476-YC 
Fig. 37: nTrip6 homo-dimerises in the nucleus 
HeLa cells were transfected with Trip6190-476 fused the N-terminal half of YFP (YN) together 
with empty vector encoding YC, or together with nTrip6 fused to YC As a transfection marker 
cells were co-transfected with dsRed-mito. The nuclei of live cells were stained with DRAQ5. 
Fluorescent images were acquired by confocal microscopy.  
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In cells transfected with either Trip6 fused to VC or transfected with Trip6 fused to VN, a 
specific staining was detectable in the cytosol. The nuclei were highlighted by DRAQ5, and 
Phalloidin rhodamine was used to illustrate the cell shape (Fig. 38). 
The fusion of Trip6 to VC or VN did not hamper the proper expression nor the localisation of 
the protein. These constructs were then used to study the dimerisation of Trip6 in the cytosol. 
 
 
 
 
 
 
 
 
 
 
 
 
In cells co-transfected with VN-Trip6 and VC-Trip6 together with mCherry as a transfection 
marker, complementation of Venus protein was detected, showing that the cytoplasmic 
protein Trip6 is also able to dimerise (Fig. 39). Surprisingly, the complementation was only 
occurring at sites of focal adhesion, but not in the cytosol, where Trip6 is also present (Fig. 
39). 
This result suggests that Trip6 dimerisation might be a regulated event at focal adhesion sites. 
This mechanism of dimerisation would then be different to the dimer formation of the nuclear 
isoform, nTrip6, for which dimerisation is always observed throughout the nucleus (Fig. 37). 
 
 
 
VC-Trip6  
+ 
VN-Trip6 
Complementation          mCherry                         merge  
Fig. 39: Trip6 dimerises at focal adhesion sites 
HeLa cells were transfected with Trip6 fused the N-terminal half of Venus (VN)
together with Trip6 fused to VC, and with mCherry as a transfection indicator. 
Fluorescent images were acquired by confocal microscopy.  
α−ΗΑ           Phalloidin        DRAQ5
VN-
Trip6 
VC-
Trip6 
Fig. 38: Fusion of Trip6 to VC or VN does
not hamper its localisation 
HeLa-ells were transfected with Trip6 fused 
to the C-terminal half of Venus (VC) or to 
the N-terminal half (VN) and probed with an 
antibody against the HA-tag. Phalloidin was 
used to show the cellular shape. The nuclei of 
live cells were stained with DRAQ5 and 
fluorescent images were acquired by confocal 
microscopy.  
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3.3.4 Dimerisation occurs at AP-1 regulated promoters 
 
If the dimerisation of nTrip6 in the nucleus is required for the co-activator function of nTrip6 
then it should occur at the promoter of activated AP-1 target genes. 
To investigate this question in living cells, I made use of a cell line containing an array of 
amplified AP-1 dependent luciferase reporter gene (-517/+63Coll-Luc). The cell line was 
generated as previously described for the uPA and MMTV array cell lines and the clone 12C 
was chosen for further investigations. 
As a first step, I confirmed the presence of the gene array by DNA fluorescent in situ 
hybridisation using a luciferase specific probe (Fig. 40). 
 
 
 
 
 
 
 
 
 
 
 
 
 
A specific staining was detected in 1 to 2 spots within the nucleus of the 12C cells, and was 
present in 100% of the cells, whereas only background staining was visible in the parental 
NIH-3T3 cells (Fig. 40). To investigate if the gene array was functional, clone 12C cells were 
treated with TPA to activate AP-1 and the luciferase activity was measured. 
 
 
 
 
 
 
 
 
 
 
 
 
 
NIH 3T3 12C blowup 
Fig. 40: DNA fluorescence in situ hybridisation (DNA-Fish) in highlights the -
517/+63Coll-Luc gene array 
Clone 12C and parental NIH-3T3 fibroblasts were subjected to DNA in situ hybridization 
using a fluorescently labelled cDNA probe complementary to the luciferase coding 
sequence. A single gene array is visible in 100% of the 12C cells. 
Coll-Luc
Fig.41: The -517/+63Coll-Luc gene array in clone 12C
is functional 
1x104 logarithmically growing 12C-cells as well as 
parental cells were seeded in a 96 well plate. 24h post 
seeding cells were serum-starved with 0,5% DCS-DMEM
and treated with the phorbol ester TPA. Luciferase activity 
was determined 16h later, and was plotted relative to the 
untreated NIH3T3 control cells. Results are presented as 
fold induction, and are the mean ± SD of a representative 
experiment performed in triplicates. 
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Treatment of the parental cell line NIH3T3 with TPA did not result in any detectable 
luciferase activity, as expected. The clone 12C showed a significant basal luciferase activity, 
which was strongly increased upon treatment of cells with TPA (Fig. 41). This result shows 
that the array is functional. I then used this array cell line to study the dimerisation of nTip6 at 
an activated AP-1 dependent promoter by using the advanced BiFC (Fig. 42). Again, the 
recruitment of GFP-PolII was used as an indicator of transcriptional activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
In cells transfected with GFP-PolII no recruitment was detectable to the array when AP-1 was 
not active, but after treatment with the phorbol ester TPA, RNA-PolII was recruited to the 
array. These enrichments were detectable in 70-80% of the transfected cells. These data 
further confirm that the array is functional and responds to TPA (Fig. 42). Transfection of 
YFP-fused Trip6190-476 resulted in a homogeneous distribution in the nucleus of untreated 
cells. Upon treatment with TPA Trip6190-476 was recruited to the array as indicated by an 
enrichment of Trip6190-476-YFP in a single spot in the nucleus (Fig. 42). This result confirms 
that nTrip6 is recruited to the promoter of AP-1 target genes in an activation-dependent 
manner. 
 
I then studied if nTrip6 is recruited to the promoter as a dimer using the BiFC system in this 
cell line. Although fluorescent complementation between Trip6190-476-YN and Trip6190-476-YC 
was detectable in the nucleus of transfected cells, no recruitment to the array was observed in 
control untreated cells. After treatment of the transfected cells with TPA, the fluorescence 
complementation was enriched at the array. This result shows that nTrip6 dimerises at the 
promoter of activated AP-1 target genes. To confirm this result, I used FRET (fluorescent 
resonance energy transfer) as another fluorescence microscopy based protein-protein 
interaction assay in the array cell line. As a FRET donor I used Trip6190-476 fused to CFP 
(Trip6190-476-CFP), as an acceptor I used Trip6190-476 fused to YFP (Trip6190-476-YFP) (Fig. 43). 
 
 
               Trip6190-476-VN 
    GFP-Pol II    Trip6190-476-YFP               + 
                                                      Trip6190-476-VC 
-TPA 
+TPA 
Fig. 42: nTrip6 dimerises at AP-1-
regulated promoters 
12C cells were transfected with, an 
expression vector for GFP-Pol II, an 
expression vector for Trip6190-476
fused to YFP or expression vectors 
for Trip6190-476 fused to the N-
terminal part of Venus (Trip6190-476-
VN) together with nTrip6 fused to 
the C-terminal part of Venus 
(Trip6190-476-VC). Cells were treated 
with TPA for 1h to activate AP-1 
and imaged by confocal microscopy. 
Nuclei of representative cells are 
shown. 
Small windows show a blowup of 
the array. 
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In transfected cells, Trip6190-476-CFP alone showed a homogeneous distribution in the nucleus 
and the signal was only detectable in the CFP-specific detection-channel. After treatment with 
TPA, Trip6190-476 was enriched at the array. No fluorescent signal was detectable within the 
YFP detection channel (Fig. 43 a)). Trip6190-476-YFP transfected alone also showed a 
homogeneous distribution in the nucleus of transfected cells and the signal was only 
detectable in the YFP-specific detection-channel. Upon treatment with TPA Trip6190-476-YFP 
was enriched at the array. No fluorescent signal was detectable in the CFP detection channel 
(Fig. 43 b)). In cells co-transfected with Trip6190-476-CFP together with Trip6190-476-YFP and 
treated with TPA, excitation at 458nm resulted in a specific fluorescent signal in the CFP 
channel (Fig. 43 c arrow). Moreover, a fluorescent emission of Trip6190-476-YFP was 
Fig. 43: Dimerisation of nTrip6 on the promoter can be detected via FRET 
1x104 12C cells were seeded in 8-well chamber slides and next day transfected with a) Trip6190-476
fused to CFP (Trip6190-476-CFP) alone, b) Trip6190-476 fused to YFP (Trip6190-476-YFP) or c) Trip6190-
476-CFP together with Trip6190-476-YFP. 2h before observation at the confocal microscope cells were 
treated with TPA to induce AP-1. 
 
a) CFP-channel setup for FRET: Trip6190-476-CFP transfected cells were excited via a 458nm laser and 
emission was detected between 460nm-475nm. The detection channel was adjusted to YFP emission 
spectra between 520nm-540nm. In cells tranfected only with CFP-nTrip6 fluorescence was only 
detected in the CFP channel and the enrichment on the promoter was visualized (arrow).   
b) YFP-channel setup for FRET: Trip6190-476-YFP transfected cells were excited via a 514nm laser 
and no emission was detected between 460nm-475nm. In cells tranfected only with YFP-nTrip6 
fluorescency was only detected in the YFP channel and the enrichment on the promoter was 
visualized (arrow).  
c) Clone 12C was double-transfected with equal amounts of Trip6190-476-CFP and Trip6190-476-YFP 
and excited with a 458nm laser and emission was detected both in the CFP and YFP channel. 
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detectable in the YFP channel. This FRET signal was detectable as a result of the interaction 
between the two transfected proteins throughout the nucleus and enriched at the array (Fig. 43 
c arrow).  
 
The results of the BiFC and FRET experiments show that nTrip6 dimerises at the promoter of 
activated AP-1 target genes. 
 
3.3.5. Mapping of nTrip6 dimerisation 
 
As a first step to address the relevance of nTrip6 dimerisation for its co-activator function for 
AP-1 target genes, it was necessary to map the dimerisation domain. 
 
3.3.5.1. The dimerisation occurs via the N-Terminus of nTrip6 
 
To study through which domain (N-terminus or LIM-domains) nTrip6 dimerises, I used the 
improved BiFC-system based on Venus, using Trip6190-476 lacking its LIM-domains (Trip6190-
476∆LIM-VC) as well as Trip6190-476 LIM-domains alone fused to the C-terminal half of Venus 
(LIM-VC), or Trip6190-476 fused to VC (Trip6190-476-VC) as a positive control. As an 
interaction partner I used Trip6190-476 fused to VN (Trip6190-476 -VN). 
I first performed antibody stainings against the HA-epitope of the fusion proteins to 
investigate their localisation in transfected cells, using phalloidin rhodamine to visualize cell 
shape and DRAQ5 to highlight the nucleus. This localisation control was particular important 
to perform, since the localisation of the putative nuclear localisation signal (NLS) within 
Trip6 sequence is still unclear. Thus, the deletion of the N-terminus or of the LIM-domains 
could result in a loss of Trip6190-476 localisation to the nucleus (Fig. 44). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HA-Trip6190-476 
-VN 
HA-LIM-VC 
HA- Trip6190-476 
∆LIM-VC 
  αHA       Phalloidin    DRAQ5 
Fig. 44: Fusion of Trip6190-476∆LIM or 
LIM to VC or Trip6190-476 to VN did not 
hamper the localisation 
HeLa-ells were transfected with Trip6190-
476∆LIM or LIM to fused to the C-terminal 
part of Venus (VC) or Trip6190-476 to the N-
terminal half VN and probed with an 
antibody against the HA-tag. Phalloidin 
was used to show the cellular shape. The 
nuclei of live cells were stained with 
DRAQ5 and fluorescent images were 
acquired by confocal microscopy.  
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The fusion of Trip6190-476to VN or VC did not hamper the proper expression nor the 
localisation of the protein as illustrated by a positive antibody staining of the fusion protein in 
the nucleus of transfected cells (Fig. 44). In cells transfected with LIM-domains alone fused 
to VC (LIM-VC) a specific antibody staining was detectable in the nucleus of transfected 
cells illustrated by DRAQ5. In cells transfected with the LIM domain deletion mutant 
Trip6190-476∆LIM-VC, a specific staining was also detectable in the nucleus (Fig. 44).  
The fusion of VC or VN to Trip6190-476 or its deletion mutants only expressing the LIM-
domains or N-terminus of Trip6190-476 did not hamper the proper expression nor the 
localisation of the protein. Thus, there might be putative NLS sequences both within the LIM-
domains and the N-terminus of Trip6. The constructs were thus suitable to use in a BiFC 
experiment (Fig. 45). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the positive control situation, when I co-transfected Trip6190-476-VN together with Trip6190-
476-VC, I detected complementation of Venus in the nucleus of transfected cells, confirming 
that Trip6190-476 forms homodimers, and that this dimerisation only occurs in the nucleus. 
When I co-transfected Trip6190-476∆LIM-VC together with Trip6190-476-VN, the 
complementation of Venus was still detectable in the nucleus (Fig. 45). However, no 
          Compl.           NES-mCherry           DRAQ5 
HA-Trip6190-476-VC 
HA-Trip6190-476-VN 
 
+ 
HA-LIM-VC 
HA-Trip6190-476 
∆LIM-VC 
Fig. 45: nTrip6 dimerises via its N-terminus, not via the LIM-Domains 
HeLa cells were transfected with Trip6190-476 fused the N-terminal half of Venus (VN) together with either 
Trip6190-476  fused to VC, Trip6190-476 ∆LIM or LIM-domains alone fused to VC. As a tranfection marker cells 
were co-tranfected with mCherry fused to a nuclear export signal (NES). The nuclei of live cells were stained 
with DRAQ5 and fluorescent images were acquired by confocal microscopy.  
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complementation of the Venus protein was detectable in cells transfected with LIM-VC 
together with Trip6190-476-VN (Fig. 45).  
Thus, these results show that, as initially hypothesised, nTrip6 dimerisation occurs through its 
N-terminus, and not via its LIM-domains. 
 
3.3.5.2. The dimerisation is mediated by two dimerisation-domains within the N-
terminus of nTrip6 
 
To elucidate the exact amino acid sequence required for the dimerisation of nTrip6, I 
performed an in vitro protein-protein interaction assay, the Peptide SPOT analyses.  
The whole amino acid sequence of Trip6 was synthesised on a cellulose membrane in single 
spots composed of 10 amino acids. The neighbouring spot contained a two amino acid shift in 
its sequence, and this procedure was carried out until the whole sequence of Trip6 was 
synthesised. The membrane was then incubated with recombinant GST-Trip6190-476. An 
interaction between nTrip6 and a specific amino acid sequence was identified by an anti-GST 
antibody, followed by ECL-detection (Fig. 46). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Two peptide sequences interacting with GST-Trip6190-476 were identified, which I called 
dimerisation domain 1 (DD1) and dimerisation domain 2 (DD2) (Fig. 46). Both domains were 
within the N-terminus and not within the LIM domains and located after the NES (101-107). 
Dimerisation domain 2 was located within the N-terminus of Trip6190-476. Surprisingly, DD1 
is not within Trip6190-476 which was used as a GST-fusion to detect the interaction. This 
strongly suggests that dimerisation through these domains is not mediated via homologous 
interactions, i.e. DD1 interacting with DD1 and DD2 with DD2, but rather via heterologous 
interactions, such as DD1 interacting with DD2. 
Fig. 46: nTrip6 dimerises in vitro via two sequences located in the N-terminus 
Peptides covering the sequence of the whole Trip6 protein were spotted on a membrane. Each spot contains 10 
amino acids, and each following spot has a 2 residues sequence-shift.  
The membrane was incubated with a GST-nTrip6-fusion protein and the interaction was detected with an anti-
GST antibody.  
Dimerisation domain 2
Dimerisation domain 1
1MSGPTWLPPK 
      GPTWLPPKQP 
            ... 
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Since the exact nature of nTrip6 was yet not identified when I performed these experiments, I 
focused on the dimerisation domain 2. This domain is present in our working tool, Trip6190-
476, whereas dimerisation domain 1 is not. I used the BiFC-system to study the in vivo 
relevance of the dimerisation motif. 
Therefore I generated a deletion-mutant lacking DD2, and fused it to the C-terminal part of 
YFP (Trip6190-476∆DD2-YC), to test its interaction with Trip6190-476-YN (Fig. 47). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the positive control situation, when I co-transfected cells with Trip6190-476-YN together 
with Trip6190-476-YC, I detected complementation of YFP in the nucleus of transfected cells, 
confirming that Trip6190-476 forms homodimers, and this dimerisation was only observed in 
the nucleus, highlighted by staining with DRAQ5 (Fig. 47). In cells co-transfected with the 
deletion mutant Trip6190-476∆DD2-YC together with Trip6190-476-YN, no complementation of 
YFP was detectable, although cells were efficiently transfected as indicated by the expression 
of dsRed mito. This result shows the relevance of DD2 in the dimerisation of nTrip6.  
 
3.3.6. nTrip6 dimerisation is essential for its co-activator function 
 
3.3.6.1 Dimerisation deficient mutants do not act as co-activators for AP-1 
 
The next step then was to address the relevance of nTrip6 dimerisation via the identified 
dimerisation domain in nTrip6 function as an AP-1 co-activator. To address this question, I 
performed a reporter gene assay using the AP-1 dependent -517/+63Coll-Luc l reporter gene.  
Fig. 47: Deletion of the dimerisation domain 2 abolishes nTrip6 dimerisation 
HeLa cells were transfected with nTrip6 fused the N-terminal half of YFP (YN), together with either 
Trip6190-476 fused to YC as a positive control or with Trip6190-476 lacking dimerisation domain 2 (Trip6190-
476∆DD2) fused to YC together with dsRed-mito as a transfection control. 
16h post transfection cells were treated with DRAQ5 to highlight the nuclei and images were acquired by 
confocal microscopy.  
 
           Compl.             dsRed-mito           DRAQ5 Trip6190-476-YN
Trip6190-476-
YC 
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Cells transfected with vector control alone (V) showed a low basal reporter activity when not 
treated with TPA. TPA treatment resulted in an increase in reporter gene activity (Fig. 48). 
This AP-1 dependent transcriptional activity was further increased by the co-transfection of 
increasing amounts of Trip6190-476, recapitulating the co-activator function of nTrip6. In cells 
co-transfected with the deletion mutant of Trip6190-476 lacking DD2 (Trip6190-476∆DD2) after 
treatment with TPA, the AP-1 transcriptional activity was strongly reduced, in a Trip6190-
476∆DD2 dose dependent manner. This dominant negative activity of Trip6190-476∆DD2 on 
AP-1 transcriptional activity shows that the dimerisation of nTrip6 via DD2 is essential for its 
function as a co-activator for AP-1, at least in the context of artificial constructs. 
 
3.3.6.2 The dimerisation of endogenous nTrip6 is essential for its co-activator function 
 
A direct way to address the relevance of the dimerisation of endogenous nTrip6 for its co-
activator function is to interfere with dimer formation. A strategy to block the dimerisation of 
endogenous nTrip6 is to use peptides that would bind to the dimerisation domain, and thus 
block or compete with the dimerisation.  
 
  Blocking peptides are able to abolish dimerisation of nTrip6 
 
Since both the nuclear and the cytosolic isoform of Trip6 do form dimers, the inhibition of 
dimerisation must be limited to the nucleus to specifically address the effect of nTrip6 
dimerisation. I therefore generated vectors expressing peptides corresponding to the 
Fig. 48: Abolishing nTrip6 
dimerisation results in loss of AP-1 
function 
HeLa cells were cotransfected with a 
luciferase reporter gene driven by a 
minimal AP-1-dependent collagenase-
1 promoter (-517/+63Coll-Luc), 
together with either empty vector (V), 
an expression vector for Trip6190-476 or 
for the Trip6190-476 dimerization-
mutant lacking the dimerisation 
domain 2 (Trip6190-476∆DD2). Cells 
were treated with TPA as indicated 
and luciferase activities were 
determined. Results are presented as 
fold induction, and are the mean ± SD 
of a representative experiment 
performed in triplicates.  
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dimerisation domains, DD1 and DD2, and fused them to the nuclear localisation signal (NLS) 
from SV40 virus to direct them exclusively to the nucleus. As a control peptide, I used the 
same constructs, but with scrambled versions of DD1 and DD2 (DD1SCR and DD2SCR), which 
have exactly the same amino acid sequence, but should not block nTrip6 dimerisation. 
Finally, all blocking peptides were fused to mCherry. This fusion allowed me to observe their 
expression and to track their subcellular localisation.  
HeLa-cells were transfected with vectors encoding for these peptides and their expression as 
well as localisation was observed 18h post transfection in living cells using a confocal 
microscope (Fig. 49). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Both, mCherry-NLS-DD1 and mCherry-NLS-DD2, as well as their respective scrambled 
controls, were expressed and detectable only in the nucleus of transfected cells (Fig. 49). 
In a next step I was interested in the properties of the designed peptides. Would they be able 
to interfere with the dimerisation of nTrip6 in the nucleus? To answer this question, I used 
again the in vivo interaction assay BiFC. HeLa cells were transfected with Trip6190-476- VC 
and Trip6190-476-VN together with either mCherry as a control, mCherry-NLS-DD1 or DD2, 
or with their scrambled versions (Fig. 50). 
Fig. 49: Expression 
and subcellular 
localisation of 
genetically encoded 
blocking peptides  
Hela cells were 
tranfected with 
expression vectors for 
the blocking peptides,
DD1 and DD2, as well 
as their respective 
scrambled controls 
(DD1SCR and DD2SCR) 
fused to a NLS 
(nuclear localisation 
signal) and imaged 18h 
post tranfection with a 
confocal laser scanning 
microscope. 
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Cells transfected with Trip6190-476-VC together with Trip6190-476-VN showed Venus 
complementation within the nucleus, highlighted by DRAQ5, in efficiently transfected cells 
demonstrated by the expression of mCherry (Fig. 50). 
By co-expressing mCherry-NLS-DD1 the dimerisation of Trip6190-476 was drastically reduced. 
In the nucleus of co-transfected cells only a very weak or even no complementation was 
observed. By co-expressing mCherry-NLS-DD2, the complementation was also reduced, but 
not as strongly as with mCherry-NLS-DD1. Co-expressing the scrambled control peptides 
mCherry-NLS-DD1SCR and mCherry-NLS-DD2SCR had no effect on Venus complementation, 
although the peptides were properly expressed and localised within the nucleus, as judged by 
the mCherry fluorescence and DRAQ5 staining (Fig. 50). 
 
To estimate the efficiency of the blocking peptides and to compare the relative efficiency of 
DD1 and DD2, I counted among the transfected, mCherry positive cells, the number of nuclei 
showing Venus complementation (Fig. 51). 
 
              V            NLS-DD1        NLS-DD1SCR             NLS-DD2        NLS-DD2SCR 
Compl. 
mCherry 
DRAQ5 
Fig. 50: Genetically encoded peptides block the dimerisation of nTrip6 
HeLa cells were transfected with Trip6190-476 fused to the N-terminal half of Venus (VN), together with Trip6190-476
fused to VC together with expression vectors for the blocking peptides, DD1 and DD2, as well as their respective 
scrambled controls (DD1SCR and DD2SCR) fused to a NLS (nuclear localisation signal) and imaged 18h post 
tranfection with a confocal laser scanning microscope. 
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In cells co-transfected with mCherry alone, 89% of the nuclei showed complementation of 
Venus protein (Fig. 51). After co-transfection of DD1, the complementation efficiency was 
strongly reduced (Fig. 51) whereas the scrambled DD1 peptide had only a minor effect on the 
dimerisation of nTrip6 (Fig. 51). In cells co-transfected with mCherry-NLS-DD2, the 
complementation within the nuclei of transfected cells was reduced, but to a weaker extend 
compared to DD1. The scrambled DD2 control peptide also had only a minor effect on the 
complementation efficiency. These results show that the blocking peptides specifically inhibit 
the dimerisation of Trip6190-476 and that DD1 is more efficient then DD2. I therefore decided 
to continue using DD1 as a blocking peptide. 
 
 Blocking peptides are able to block AP-1 function 
 
The next step was to study if blocking the dimerisation of endogenous nTrip6 by the DD1 
blocking peptide would have an effect on nTrip6 co-activator function for AP-1. 
To test this hypothesis, I transfected HeLa-cells with the AP-1 dependent -517/+63CollI-Luc- 
reporter gene and co-transfected increasing amounts of either mCherry-NLS-DD1 or its 
scrambled control (Fig. 52). 
 
 
 
 
 
 
 
 
 
 
Fig. 51: Quantification of the effect of the 
blocking peptides on nTrip6 dimerisation 
HeLa cells were transfected as indicated in 
the legend of Fig. 50. 
 
The efficiency was calculated as the 
percentage of transfected cells (mCherry 
positive) showing Venus complementation. 
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The transcriptional activity of vector control transfected cells (V) showed a weak level, which 
was strongly increased after treatment with TPA leading to activation of AP-1. Co-
transfection of increasing amounts of mCherry-NLS-DD1 had no effect on the basal reporter 
activity, but after TPA treatment, a strong inhibitory effect on AP-1 function was observed as 
compared to vector transfected cells, and this effect was dose-dependent. The scrambled 
control peptide transfected cells showed no alteration in the reporter gene activity after 
treatment with TPA, as expected (Fig. 52). 
Thus, the dimerisation of endogenous nTrip6 is essential for its co-activator function for AP-
1. 
 
3.3.7. nTrip6 dimerisation promotes the recruitment of other proteins to AP-1 activated      
promoters 
 
Since nTrip6 does not contain any known functional domain, which could account for its co-
activator like function, we postulated that it functions by recruiting other co-activators to the 
promoters. I now have shown that nTrip6 dimerisation is essential for its co-activator 
function. It is thus reasonable to assume that the dimer formation is essential for the 
recruitment of the other co-activators, and that the blocking-peptides will compete with these 
recruitments. 
Fig. 52: Inhibition of nTrip6 dimerisation results in repression of AP-1 target genes 
HeLa cells were cotransfected with a luciferase reporter gene driven by a minimal AP-1-
dependent collagenase-1 promoter, together with either empty vector (V) or increasing 
amounts of controll-peptide (NLS-DD1SCR) or blocking peptide (NLS-DD1). Cells were 
treated with TPA as indicated and luciferase activities were determined. Results are 
presented as fold induction, and are the mean ± SD of a representative experiment performed 
in triplicates.  
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To address this question I used the DNA-pulldown method. A biotinylated DNA-fragment 
containing a TRE-site, a TATA-box and a part of the luciferase coding sequence, was used as 
a template to allow the assembly of AP-1, nTrip6 and the co-activator complexes in vitro after 
incubation with nuclear extracts of TPA treated HeLa cells, or of untreated cells as control. 
The incubation was performed in the presence of increasing concentrations of synthetic 
blocking peptide DD1. Then the proteins assembled on the DNA template were eluted, 
separated on an SDS-PAGE and revealed by silver staining (Fig. 53). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
By incubation of the biotinylated DNA template with nuclear extracts of control untreated 
cells, only a weak recruitment of proteins to the DNA-bait was observed. Incubation of the 
template with TPA treated nuclear extracts led to the assembly of multiple proteins. This 
presumably includes AP-1 co-activators.  
After co-incubation of the TPA treated nuclear extracts with increasing amounts of the 
blocking peptide DD1, some discreet protein bands were reduced in their intensity in a DD1 
dose-dependent manner, reflecting a lower amount of these proteins recruited to the promoter 
(Fig. 53).  
Fig. 53: The blocking peptide DD1 
interferes with protein assembly on the 
promoter of AP-1 target genes in vitro 
A biotinylated DNA bait composed of a 
TRE, a TATA box and a fragment of 
luciferase coding sequence was incubated 
with nuclear extracts of control cells (lane 1) 
or of cells treated with TPA (lane 2-6) in the 
presence of increasing amounts (from 
0,01mM lane 6 to 1mM lane 3) of synthetic 
DD1 peptide. The DNA-protein complexes 
where purified by using streptavidin coated 
magnetic beads , and the bound proteins were 
eluted and resolved by SDS-page and 
visualized by silver staining. 
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Thus, the dimerisation of nTrip6 is required for the recruitment of specific proteins to an AP-1 
dependent promoter, at least in vitro. Only the identification of these proteins, by mass 
spectrometry, will allow to conclude that they are nTrip6-dependent AP-1 co-activators. 
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4. Discussion 
 
4.1. nTrip6 acts as a transcriptional co-activator  
 
The AP-1 family of heterodimeric transcription factors has been extensively studied regarding 
the physiological and pathological functions of the different dimers (Eferl and Wagner, 2003; 
Hess et al., 2004). However, little is known about the specific regulation of different dimers 
when bound to DNA. In particular, an open question is whether their function requires dimer-
specific co-activators. Some known AP-1 co-activators exert their function independently of 
the dimer composition. For instance, CBP/p300 and Src1 interact with and co-activate c-Jun, 
c-Fos as well as ATF2 (Arias et al., 1994; Bannister et al., 1995; Duyndam et al., 1999; Lee et 
al., 1998). For other AP-1 co-activators, the specificity has not been addressed. The first 
question addressed in this work concerned the specificity of nTrip6 co-activator function for 
the different AP-1 dimers.  
Based on in vitro protein-protein interaction studies, Christine Heilbock (Heilbock, 2004) 
could show that nTrip6 selectively interacts only with members of the Fos family, 
respectively c-Fos, Fra 1 and 2. Although based on in vitro interaction assays with AP-1 
monomers, these results strongly suggested that nTrip6 might be a selective co-activator for 
Fos containing dimers. This hypothesis was strengthened by the observation that increasing 
the protein-level of nTrip6 leads to an increased transcriptional activity of c-Jun:c-Fos, but not 
of c-Jun:ATF2.  
During this PhD work I showed that nTrip6 selectively interacts in vivo with c-Jun:c-Fos but 
not with c-Jun:ATF2. Furthermore in the uPa-promoter gene array cell line nTrip6 was only 
recruited to the promoter when the promoter was bound by c-Jun:c-Fos, but not when bound 
by c-Jun:ATF2, although this dimer was functionally recruited to the promoter. 
Together, these results show that nTrip6 is a selective co-activator for Fos containing dimers 
(Diefenbacher et al., 2008). nTrip6 does not harbour any known co-activator function and 
serves as a bridging factor, leading to the recruitment of other yet unknown co-activators or 
even co-activator complexes. Given that nTrip6 exerts this function selectively for Fos-
containing AP-1 dimers, it is likely that other co-activators or co-activator complexes are also 
recruited in an AP-1 dimer selective manner. However, one cannot exclude the possibility that 
another protein exerts the same function, i.e. recruits the same co-activators, for dimers not 
containing Fos, like for example another LIM domain protein. 
Since nTrip6 is a specific co-activator limited to AP-1 dimers containing Fos family members 
the selective manipulation of this interaction could be used to affect only the function of 
certain AP-1 dimer pairs. c-Jun:Fra2 and c-Jun:ATF2 dimers play distinct, complementary 
roles in oncogenesis by inducing either anchorage independence or growth factor 
independence, respectively. v-Jun:ATF2 rather than v-Jun:Fra2 triggers the development of 
primary fibrosarcomas in the chicken wing (van Dam and Castellazzi, 2001). These results 
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were obtained by using artificial AP-1 family members with altered or modified properties. 
Therefore targeting nTrip6, for instance by the usage of blocking peptides, might allow us to 
discriminate the functions of endogenous AP-1 dimers containing or not containing Fos 
family members. 
 
However, interfering with the co-activator function of nTrip6 to discriminate between the 
different functions of the different AP-1 dimers might not be specific enough. Manipulating 
nTrip6 function might also interfere with the transcriptional activity of other transcription 
factors. nTrip6 is also a co-activator for NF-κB (Kassel 2004), and I report here that nTrip6 
also serves as a co-activator for GR. 
During this PhD work I showed that nTrip6 interacts in vivo with the glucocorticoid receptor 
in the nucleus upon activation. Furthermore I could confirm in vivo the interaction domain of 
nTrip6, the LIM-domain 3, as the essential protein-protein interaction surface with GR. This 
interaction is functional since overexpression of nTrip6 increases the transcriptional activity 
of GR. In the 7m gene array cell line nTrip6 was recruited to the promoter when only GR was 
bound to the promoter. Additionally I was able to show that nTrip6 and GR form a complex 
and are present at a promoter containing a GRE. 
Together, these results show that nTrip6 is a co-activator for GR. As in the case of AP-1, this 
co-activator function most likely results from the recruitment of other co-activator or co-
activator complexes. The different classes of co-activators have been extensively studied for 
their effect on GR (Kassel and Herrlich, 2007; Liberman et al., 2007). Which of these co-
activators are recruited in a nTrip6 dependent manner to GR occupied promoters remains to 
be addressed.  
nTrip6 is not the only LIM-domain protein fulfilling the function of a co-activator for GR. 
The LIM-domain protein Hic-5, first identified as androgen receptor co-activator 55 (ARA55) 
(Yang et al., 2000), is capable of regulating the transcriptional activity of all steroid receptors, 
including GR (Guerrero-Santoro et al., 2004; Heitzer and DeFranco, 2006a, b; Kim-
Kaneyama et al., 2002). Following the recruitment of Hic-5, different other co-activators are 
recruited in a Hic-5 dependent manner, like CBP/p300 or TIF-2, to a GR-occupied promoter 
(Heitzer and DeFranco, 2006b). This might suggest that different LIM-domain proteins would 
be responsible for the recruitment of different co-activator complexes during the course of the 
sequential activation of transcription by GR. A similar recruitment of different complexes by 
different LIM-domain proteins might also hold true for AP-1. Indeed, there are also other 
LIM-domain proteins which serve as transcriptional co-activators for AP-1. For example, the 
“four-and-half-LIM domain protein 2”, FHL2, associates with both Jun and Fos in vitro and 
in vivo. FHL2 stimulates Fos- and Jun-dependent transcription, thereby acting as a co-
activator of AP-1 function (Morlon and Sassone-Corsi, 2003). Given that FHL2 consists of 
only LIM domains, it is obvious that its co-activator function stems from its ability to interact 
with and recruit other co-activators to the promoter. FHL2 has indeed been shown to interact 
with CBP/p300 (Labalette et al., 2004). Thus, the function of LIM domain proteins in 
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transcriptional regulation is most likely to mediate the sequential recruitment of different co-
activator complexes to target promoters. 
Does a given LIM-domain protein mediate the recruitment of always the same co-activator 
complex, independent of the transcription factor? This is probably not the case, as illustrated 
by the different functions that the same LIM-domain protein can exert for different 
transcription factors. For example, the LIM only protein LMO4 is, on the one hand, a 
transcriptional co-activator for Smad transcription factors (Lu et al., 2006), on the other hand 
LMO4 is involved in the negative regulation of estrogen receptor alpha trans-activation 
function, in a histone deacetylases-dependent manner (Singh et al., 2005). The LIM-domain 
protein Hic-5, which is able to function as a transcriptional co-activator for AR and GR, 
mediates the repression of other transcription factors. The activation of Wnt/beta-catenin 
target genes is regulated by a heterodimer of beta-catenin and the high mobility group box 
transcription factors of the lymphoid enhancer factor (LEF)/T-cell factor (TCF) family. Hic-5 
was identified to interact with these transcription factors and to act as a negative regulator of a 
subset of LEF/TCF family members (Ghogomu et al., 2006). These examples strongly 
suggest that the proteins recruited to promoters by LIM-domain proteins also depend on the 
transcription factor, or on the chromatin context. 
 
4.2. nTrip6 is essential for the “crosstalk” between GR and other 
transcription factors 
 
nTrip6 does not only serve as a transcriptional co-activator for AP-1, NF-κB and GR, it is also 
involved in the negative crosstalk between these transcription factors, namely the trans-
repression of AP-1 and NF-κB by GR, and the trans-repression of GR by AP-1 and NF-κB. 
Here, nTrip6 mediates the tethering of the repressing transcription factor to the chromatin-
bound repressed transcription factor.  
During this PhD work I showed that the ability of GR to tether to and to trans-repress 
different AP-1 dimers strictly depends on the interaction of the AP-1 dimer with nTrip6. In 
the 2uPa gene array cell line, nTrip6 was recruited to c-Jun:c-Fos bound promoters, but not to 
c-Jun:ATF2 bound promoters. Only if nTrip6 was recruited was GR able to tether to the 
promoter and to repress transcription (Diefenbacher et al., 2008). Thus, nTrip6 is responsible 
for the very first step in trans-repression, by providing a platform for the tethering of the 
repressing transcription factor. 
 
AP-1 and NF-κB are not only trans-repressed by GR, these transcription factors are also able 
to trans-repress the nuclear receptor as well (Burkhart et al., 2005; Hofmann and Schmitz, 
2002; Lucibello et al., 1990; McKay and Cidlowski, 2000; Schule et al., 1990). By making 
use of the 7m-gene array cell line, I could demonstrate that c-Fos is recruited to the promoter-
bound GR, and that nTrip6 is present at this promoter at the same time. Upon the recruitment 
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of c-Fos to the promoter the transcriptional activity of GR was repressed. Furthermore, after 
mutation of LIM-domain 1 of nTrip6, which is essential for the interaction with c-Fos or p65 
(Kassel et al., 2004), c-Fos was no more able to repress the transcriptional activity of GR 
(Heilbock, 2004), confirming the involvement of nTrip6 in the crosstalk. Taken together, 
these observations strongly suggest that nTrip6 mediates the tethering of c-Fos to promoter-
bound GR, as a first step in the trans-repression of GR by c-Fos. Thus the trans-repression of 
GR by AP-1 uses the same mechanisms, at least for the first step, than the trans-repression of 
AP-1 by GR: the nTrip6-dependent tethering of the repressing transcription factor to the 
promoter-bound repressed transcription factor. 
 
nTrip6 is able to influence the transcriptional activity of its interaction partners in a protein-
protein interaction dependent context. It mediates on the one hand the activation, on the other 
hand it is essential for the repression of its interacting transcription factors. Another LIM-
domain family member shows the same features, the context dependent involvement in 
activation and repression: Hic-5. As mentioned above, Hic-5 is able to increase the 
transcriptional activity of several nuclear receptors, including GR (Yang et al., 2000). But it is 
also mediating the repression of a subset of LEF/TCF family members (Ghogomu et al., 
2006). Furthermore, like nTrip6, Hic-5 is essential for the repression of glucocorticoid-driven 
transcription through LEF/TCF family members, which again could be allocated to specific 
LEF/TCF subtypes (Ghogomu et al., 2006). Thus, the ability of multiple LIM-domain 
proteins to interact with several transcription factors to positively or negatively influence their 
transcriptional activity depending on the cellular context provides a mechanism for the fine 
tuning of the transcriptional response. 
 
GR can trans-repress and is trans-repressed by transcription factors other than AP-1 and NF-
κB. For example, GR trans-represses the pituitary specific factor Pit-1 (Nalda et al., 1997). 
Glucocorticoids were proposed to repress proopiomelanocortin (POMC) gene expression via 
the trans-repression by GR of the orphan nuclear receptor NGFI-B (Martens et al., 2005). The 
Spi-1/PU.1 protein, an Ets-related transcription factor, can specifically repress the 
glucocorticoid-induced activation of promoters carrying a glucocorticoid response element 
(GRE). Conversely, GR represses Spi-1/PU.1-mediated transcriptional (Gauthier et al., 1993). 
The repression by GR of the expression of TGF-beta responsive genes containing binding 
sites for the transcription factors Smad3/4 has been attributed to the interaction between GR 
and Smad3 (Song et al., 1999). GR trans-represses and is trans-repressed by the T cell 
transcription factor T-bet (Liberman et al., 2007). In lymphocytes, glucocorticoids suppress 
IL-4-induced trans-activation of a signal transducers and activators of transcription 6 
(STAT6)-responsive promoter without affecting IL-4-stimulated STAT6 DNA-binding. This 
is mediated via a physical association between GR and STAT6. Reciprocally, STAT6 
overexpression increased the IL-4 inhibitory effect on glucocorticoid-induced MMTV trans-
activation. (Biola et al., 2000).  
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Since the reciprocal trans-repression between AP-1, NF-κB and GR requires nTrip6 as a 
tethering factor, one might also hypothesise a similar role for nTrip6, or for other LIM-
domain proteins in the crosstalk between GR and these other transcription factors.  
 
Similarly, other nuclear receptors than GR can trans-repress AP-1 and NF-κB. For example, 
the thyroid hormone (T3) receptor (TR) is capable of interfering with the transcriptional 
activity of AP-1, and vice versa, the transcriptional activity of the thyroid receptor can be 
inhibited by AP-1 (Zhang et al., 1991). Given that Trip6 was first identified as a TR 
interacting protein (Lee et al., 1995), one could also hypothesise a role for nTrip6 in the 
crosstalk between TR and AP-1. Another nuclear receptor that can repress AP-1 is the 
androgen receptor (AR) (Fronsdal et al., 1998; Kallio et al., 1995; Saatcioglu et al., 1994). 
Furthermore, the transcriptional activity of the AR is repressed by c-Fos (Mora and Mahesh, 
1996). In vitro interaction studies could show an interaction between AR and nTrip6 
(Heilbock, 2004). Thus nTrip6 might be the tethering protein between AR and AP-1. 
Conversely, in vitro, nTrip6 does not interact with the mineralocorticoid receptor (MR) 
(Heilbock, 2004), and this receptor does not trans-repress AP-1 (Gougat et al., 2002).  
Thus, the interaction with LIM-domain proteins such as nTrip6 might be a general 
requirement for the crosstalk between nuclear receptors and other transcription factors. 
 
Another still open question is the mechanism of trans-repression. The first step is the tethering 
of the repressing transcription factor to the promoter-bound transcription factor. But how is a 
transcriptional active complex turned into an inactive state after the recruitment of another 
active transcription factor? What is the role of nTrip6? Is it a general key-player in the 
crosstalk between GR and different transcription factors? We could show that nTrip6 
functions as a co-activator for the different transcription factors, via the recruitment of other 
co-activators. Thus, one possibility might be that upon tethering of the repressing 
transcription factor via its interaction with nTrip6, it blocks the recruitment of the other co-
activators. Alternatively, the tethered repressing transcription factor might mediate the 
recruitment of other factors with repressing properties.  
 
4.3. nTrip6: Mechanism of transcriptional regulation 
 
Since nTrip6 does not carry any known co-activator domain or function, we hypothesised that 
it exerts its action by mediating the recruitment of other co-activators, acting as a “co-
activator platform”. The three LIM domains of nTrip6 are the only known protein interaction 
domains within the protein, making them good candidates for the interaction with other co-
activators. Indeed, during this work I could show that the LIM-domains of nTrip6 are 
sufficient, and the N-terminus dispensable for its autonomous co-activator function. However, 
I also demonstrated that the N-terminal part of nTrip6, which does not harbour any known co-
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activator like domain, is also required for the co-activator function: when this part of nTrip6 
was deleted, the transcriptional activity of AP-1 was not further increased. Because of this 
discrepancy I raised the hypothesis that nTrip6 might have to dimerise via its N-terminus to 
exert its co-activator like function. Based on in vivo interaction assays in combination with 
the gene array cell line 12C, I could demonstrate that nTrip6 forms a homo-dimer, and this 
dimer is recruited to the activated AP-1-dependent promoter. Two dimerisation domains, 
DD1 and DD2, were identified. Both domains are within the N-terminus of Trip6 and are 
located after the NES. Deletion of the dimerisation domain led to a loss of dimerisation and 
resulted in the loss of the co-activator function for AP-1. Interestingly, the deletion mutant 
had a dominant negative effect on the transcriptional activity of AP-1. This might be due to 
the squelching of co-activators away from the promoter by the dimerisation deficient protein, 
which still contains its LIM-domains. By using genetically encoded blocking peptides 
composed of the dimerisation domain fused to a nuclear localisation signal I was able to 
interfere with the dimerisation of nTrip6. Furthermore, by using these blocking peptides I was 
able to interfere with the dimerisation of endogenous nTrip6 resulting in an inhibition of AP-1 
target genes. 
 
These results clearly demonstrate that nTrip6 dimerisation through its N-terminus is essential 
for its co-activator function for AP-1. The role of nTrip6 dimerisation for its co-activator 
function for other transcription factors such as NF-κB and GR remains to be confirmed. Since 
the interaction domains of nTrip6 are its LIM-domains, the possible protein interactions at the 
same time are limited by the amount of LIM-domains available. The LIM-domain 1 is 
required for interaction with the transcription factors c-Fos or NF-κB/p65, whereas the LIM-
domains 2 and 3 are required for the interaction with GR (Kassel et al., 2004). Thus, when 
nTrip6 is tethered to a promoter through its interaction with a transcription factor, its LIM 
domains are engaged in the interaction, and not available to recruit additional co-activators. 
Through dimerisation three additional LIM-domains are present at the promoter, and free to 
interact with other co-activators. Thus, although not formally proven, nTrip6 dimerisation is 
most likely essential for the recruitment of other co-activators to the regulated promoters. In 
favour of this hypothesis, I showed that nTrip6 dimerisation is required for the recruitment of 
several proteins on an AP-1- regulated promoter in vitro. It now remains to be demonstrated 
that these proteins are indeed co-activators, and to confirm that they are recruited in a nTrip6 
dimerisation-dependent manner to AP-1-regulated promoters in vivo, using the gene array cell 
line for example. Another LIM-domain protein, Hic-5, was shown to interact both with GR 
and with co-activators like CBP/p300 on activated GR-dependent promoters. Furthermore, 
deletion of the LIM domain 4 of Hic-5 interfered with the co-activation properties of p300, 
suggesting a functional interaction between these co-activators. Hic-5 is also recruited to the 
c-fos promoter, however, here a different subset of co-activators is recruited in a Hic-5 
dependent manner (Heitzer and DeFranco, 2006b). Thus, the set of co-activators recruited 
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through an interaction with a LIM-domain protein does not depend only on the nature of the 
LIM-domain protein, but also on the nature of the regulated transcription factor. 
 
Also notably is the oligomerising ability of Hic-5. This dimerisation is different from the 
homo-dimerisation observed for nTrip6: it is attributed to the most C-terminal LIM domain, 
LIM domain 4, which is uniquely multifunctional. In addition to serving as an interface for 
interaction with itself and with the LIM-domain protein PINCH and ILK, it is implicated in 
the scaffold function of Hic-5 in the nucleus to assemble transcriptional complexes 
(Shibanuma et al., 2004) and in the association of Hic-5 with the nuclear matrix (Guerrero-
Santoro et al., 2004). These functions of Hic-5 mediated by LIM domain 4 might be coupled 
with its homo- and hetero-oligomerisation (Mori et al., 2006). Only when able to form homo- 
or heterodimers Hic-5 is capable to serve as a transcriptional co-activator for GR (Mori et al., 
2006). Since Hic-5 does hetero-dimerise with other LIM-domain proteins (Mori et al., 2006), 
it would be interesting to investigate whether nTrip6 is capable of interacting with other LIM-
domain proteins as well. Based on sequence alignments the first candidate to test this 
hypothesis would be the closely related LIM-domain protein LPP which shares similar 
domains with nTrip6, including the dimerisation domains, and also functions as a co-activator 
(Petit et al., 1996). Another interesting interaction partner would be LMO4 (Lu et al., 2006). 
Both, LMO4 and nTrip6 interact with GR, GR represses TGF-beta signalling by repressing 
Smad 3/4 (Song et al., 1999) and LMO4 functions as a co-activator for Smads (Lu et al., 
2006). Is the crosslinking of the activating and repressing transcription factors mediated via a 
hetero-dimer between nTrip6 and LMO4? To test both hypothesis, the interaction between 
nTrip6 and LPP or LMO4, in vivo interaction assays like described in this work are suitable to 
answer that question. Furthermore, by performing chromatin immunoprecipitations (ChIP) or 
by generating gene array cell lines containing Smad REs the complex formation between the 
different proteins on Smad-regulated promoters could be identified. And finally, the use of the 
blocking peptides would enable to investigate the role of heterodimer formation. 
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Conclusion 
 
In this work I showed that nTrip6 act as a selective co-activator for a subset of AP-1 dimers. 
Moreover, the interaction of AP-1 dimers with nTrip6 determines the ability of GR to trans-
repress these AP-1 dimers, since GR is tethered to the promoter via its interaction with 
nTrip6. Similarly, nTrip6 acts as a co-activator for GR, and mediates the tethering of AP-1 
and NF-κB to promoter-bound GR, as a first step in the trans-repression of GR by AP-1 and 
NF-κB. The co-activator function of nTrip6 necessitates its dimerisation through two 
dimerisation domains in its N-terminus. This dimerisation enables the recruitment of other 
proteins, presumably co-activators, to the promoter. These properties of nTrip6 are most 
likely common to other LIM-domain proteins. The ability of transcription factors to interact 
with several LIM-domain proteins enables fine tuning of the transcriptional response, by the 
recruitment of different co-activator complexes, and by the possibility of repressing crosstalks 
with other transcription factors. 
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Fig. 54: The role of nTrip6 in the regulation of AP-1 and GR transcriptional activity 
a) nTrip6 functions as a transcriptional co-activator 
1) nTrip6 functions as a selective co-activator for Fos-family member containing AP-1 dimers. nTrip6 is 
recruited as a dimer to AP-1-occupied promoters, and increases the transcriptional activity by recruiting other 
co-activators 
2) nTrip6 is a novel co-activator for GR, Similarly, nTri6 acts as a co-activator for GR. Here the dimerisation of 
nTrip6 has not been demonstrated and is only putative 
 
b) nTrip6 mediates the crosstalk between different transcription factors 
3) GR is tethered to promoters bound by AP-1 in a nTrip6 dependent manner, as a first step in the trans-
repression of AP-1 activity. 
4) Similarly, AP-1 trans-represses GR by tethering to the promoter via an interaction with nTrip6 
TRE: TPA response element; GRE: glucocorticoid response element
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